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ABSTRACT
ULTRASOUND INDUCED PHASE CHANGE OF EMULSION DROPLETS FOR
TARGETED GENE- AND DRUG-DELIVERY
James R. Lattin
Department of Chemical Engineering, BYU
Doctor of Philosophy
This dissertation explores the potential of using perfluorocarbon emulsion droplets to add
an ultrasound-sensitive element to drug delivery systems. These emulsion droplets may be
induced to vaporize with ultrasound; during the rarefactional phase of an ultrasound wave, the
pressure around the droplets may fall below the vapor pressure of the liquid forming the
emulsion, providing a thermodynamic potential for vaporization. This ultrasound-induced phase
change of the emulsion droplet could release therapeutics attached to the droplet surface or aid in
drug delivery due to mechanical effects associated with vaporization and expansion, similar to
the ability of cavitating bubbles to aid in drug delivery. In contrast to bubbles, stable emulsions
can be formed at nano-scale sizes, allowing them to extravasate into tissues and potentially be
endocytosed into cells. Perfluorohexane and perfluoropentane were selected to form the
emulsions due to their relatively high vapor pressure, low water solubility, and biocompatibility.
Acoustic droplet vaporization was explored for its potential to increase ultrasoundinduced drug release from liposomes. Liposomes have proven to be versatile and effective drug
carriers, but are not inherently responsive to ultrasound. eLiposomes, defined as a liposome with
encapsulated emulsion droplets, were developed due to the potential of the expanding vapor
phase to disrupt bilayer membranes. The resulting vesicle retains the advantages of liposomes
for drug delivery, while adding an ultrasound-sensitive element. eLiposomes were loaded with
calcein, a fluorescent molecule, as a model drug in order to quantify ultrasound-mediated drug
release compared to release from conventional liposomes. Upon exposure to ultrasound,
eLiposomes typically released 3 to 5 times as much of the encapsulated load compared to
conventional liposomes, with some eLiposome samples approaching 100% release. Emulsion
droplets were also added to the outside of conventional liposomes, but resulted in little to no
increase compared to control samples without emulsions.
Lastly, in vitro experiments were performed with HeLa cells to explore the ability of
emulsion droplets and eLiposomes to deliver calcein inside of cells. Calcein delivery to the
cytosol was accomplished, and the emulsion-containing samples demonstrated the ability to aid
in endosomal escape.
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1

INTRODUCTION

Targeted drug delivery is currently an important and promising research area. There are
a number of conventional and potentially useful therapeutic techniques that sometimes have
widespread negative side effects and risks. These techniques often have a specific target, such as
a cancerous tumor or a specific target organ where treatment is beneficial. Side effects and risks
could be greatly reduced if the therapeutics could be directed specifically to the target area. One
of the most obvious examples of this is chemotherapy used in cancer treatment. The devastating
side effects of this treatment include fatigue, hair loss, widespread pain, sores, diarrhea, nausea,
and vomiting. If the chemotherapy drugs could be delivered only to the cancer cells, then the
benefit of this treatment could be maintained while avoiding most of the negative side effects.
Another major candidate for targeted delivery is gene therapy. This treatment allows
selected genes to be inserted into a patient’s cells. These inserted genes may replace abnormal
genes, turn on inactive genes or suppress a disease-causing gene. Heart disease, lung disease,
cancer, and genetic disorders are just a few of the diseases that could be targeted with such a
treatment. However, because of potential negative effects of exposing the entire body to these
foreign therapeutic genes, they should be delivered only to the target cells.
For the last decade, ultrasound has been investigated as a targeting modality for drug and
gene delivery to preferentially deliver therapeutics to a specific target. Ultrasound has been
shown to temporarily increase the permeability of cell membranes, allowing for more effective
1

delivery of therapeutics to the area exposed to ultrasound. Cavitation is believed to be the
mechanism that causes this permeability. Cavitation is the formation, vibration, and collapse of
bubbles caused by pressure oscillations in the ultrasonic field. It is believed that cavitation
events introduce mechanical shear that temporarily creates tears and holes in the cell membrane,
increasing the delivery of therapeutics to the interior of the cell.
Ultrasound can also aid in drug and gene delivery by breaking apart or otherwise
activating a vesicle serving as a drug carrier, thus releasing the drug in the specific location
where ultrasound is applied. These drug carriers can be micelles, polymer particles, liposomes,
or bubbles. Bubbles are of particular interest as ultrasound activated drug carriers because they
can serve as cavitating bubbles while simultaneously carrying drugs. One disadvantage to
bubbles, however, is that they cannot easily be formed at sub-micron sizes due to the high
Laplace pressure found in small bubbles. This minimum size limitation prevents bubbles from
being able to pass beyond capillaries into tissues where delivery is desired because the junctions
between endothelial cells lining normal capillaries are typically less than 10 nm in size.
Microbubbles are even excluded from cancerous tumors, despite the potential for cancerous
tissues to have large capillary fenestrations of up to 1000 nm [1].
Another useful carrier that has been investigated in drug delivery is a liposome.
Liposomes can be loaded with drugs or DNA, sequestering the therapeutics inside of a bilayer
lipid membrane until they are released from the liposome. Liposomes have many advantages,
including a high encapsulation efficiency, relative low cost, and biocompatibility of lipids.
Perhaps the most-often cited advantage for cancer treatment is that their sub-micron size allows
liposomes to permeate deep into tissues, especially cancerous tumors with leaky capillaries.
These advantages have led to the active research of liposomes as drug carriers for decades.
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However, one disadvantage of liposomes is that drug delivery is achieved by gradual diffusion
out of the liposome or the eventual rupture or break down of the membrane over time. While
liposomes are very useful as drug delivery vehicles, their potential in targeted delivery could be
increased if drug release could be induced by ultrasound.

One way to make liposomes

susceptible to ultrasound may be to encapsulate emulsion droplets with a relatively high vapor
pressure inside of the liposomes. During the low pressure phase of the acoustic cycle the
encapsulated liquid will vaporize, resulting in a sufficient volume of gas to break apart the lipid
bilayer of the liposome, allowing targeted drug release from the liposome. This release would be
localized to where the ultrasound was applied, and the time and rate of release could be
controlled by ultrasound.

Throughout the rest of this dissertation, liposomes containing

encapsulated emulsion droplets will be referred to as eLiposomes.
This vaporizing fluid could also address another concern with drug delivery: endosomal
escape. Drugs that cannot diffuse through cell membranes often enter the cell through an
endosome, where they are digested and broken down by the cell before they can be
therapeutically effective. If several emulsion droplets were trapped within a liposome inside of
the endosome, they could provide sufficient volume increase during vaporization to not only
break through the liposomal membrane, but also to break open the bilayer membrane of the
endosome, thus allowing release of the drug into the cell cytosol.
My dissertation research has included the synthesis of perfluorocarbon emulsions and the
synthesis of eLiposomes. Nano-scale perfluorocarbon emulsions were formed and characterized.
Once formed, eLiposomes were investigated as ultrasound activated drug carriers. The ability of
eLiposomes to deliver model drug in vitro and the ability of expanding emulsion droplets to aid
in endosomal escape was also investigated.

3

2

LITERATURE REVIEW AND BACKGROUND

2.1 Drug and gene delivery
Chemotherapeutic drugs are one of the main treatments used against cancerous tumors.
However, this treatment is often limited by the high toxicity of the drugs and the lack of tumorspecific targeting [2]. Current chemotherapy techniques usually involve systemic circulation of
the drug. This exposes the whole body to the chemotherapy, resulting in anemia, vomiting,
diarrhea, nausea, and hair loss [3]. Methods for targeting drugs to specific target sites are an
active research area. The goal of this research is to selectively deliver drugs to tumors without
harming other cells. By targeting the drug to the tissue where it is needed, the dose delivered to
the target tissue could be maintained or even increased while lowering exposure in other areas of
the body. Alternatively, a reduced administered dose could be used to achieve a therapeutic dose
at the target site. This would allow for more effective treatment of the tumor while reducing or
eliminating negative side effects [4].
Another type of treatment requiring targeting is gene therapy. In this treatment selected
genes are transfected into a patient’s cells. Transfection is the incorporation of foreign genetic
material into a cell. These inserted genes may replace abnormal genes, suppress active genes or
stimulate inactive genes. In principle, inserted genes may code for specific proteins that would
allow a wide variety of problems to be alleviated at the cellular level. The treatment of cancer,
infectious diseases, liver diseases, vascular diseases, and genetic disorders are just a few of the
4

potential uses for such a treatment [5, 6]. However, the effect of exposing the entire body to
foreign DNA that is designed to be therapeutic for a certain type of tissue is a major concern. It
is important to be able to deliver the genetic material to the targeted cells without delivery to the
rest of the body. The most promising method for delivery of therapeutic genes was previously
thought to be viral vectors. Because this method utilizes an efficient viral mechanism for
inserting genetic material into cells, viral delivery has been shown to have very high transfection
rates [6]. However, this method has a number of drawbacks, including toxicity of viral vectors
and decreased efficiency of treatments over time due to the body’s immune response. Also, viral
delivery methods have very low tissue specificity, raising safety concerns about the effects of the
inserted genes on non-targeted cells, and the potential of these genes being integrated into the
patient’s cells at random sites in the body [7].
Over the last decade, non-viral drug targeting carriers for both conventional drugs and
nucleic acids have been an area of intense research. Drug delivery systems seek to increase sitespecific delivery and to sequester the drug load except at the target site. Potential targeting
techniques that have been investigated include attaching a targeting ligand to the surface of the
drug carrier, using a pH-sensitive or enzyme activated carrier, targeting leaky tissues by
controlling the carrier size, and making the carrier susceptible to drug release when an external
trigger is applied [4, 8, 9]. “Passive targeting” typically refers to drug carrier accumulation in
some tissues based on the size of the particle and the inherent properties of the target tissue’s
vasculature.

In “active targeting,” ligands are recognized by a target cell type and aid in

preferential attachment and sometimes induce uptake of the therapeutics into targeted cells [1012]. Enzyme or pH-sensitive carriers are designed to sequester drugs until release is triggered at
the targeted location by environmental changes [13, 14]. “Actuated” delivery, the use of an
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external trigger such as ultrasound, has the advantage of being able to control both the location
of release and the amount of drug released with time [9]. Multiple targeting techniques can also
be used in conjunction with each other, such as using passive targeting to concentrate drug
carriers at a target site and then releasing sequestered drug by employing active or actuated
targeting.
Sub-micron drug and gene carriers are especially desirable for cancer treatments in order
to take advantage of passive targeting. Cancer tumors tend to have chaotic and rapidly growing
vasculature. The chaotic growth of tumor vessels leads to a leaky capillary system with large
fenestrations that allow sub-micron particles to pass into the cancerous tissue.

The poor

development of an efficient lymphatic system for clearance from the tumor allows particles that
are on the order of hundreds of nanometers to accumulate in the tumor. This is referred to as the
enhanced permeability and retention (EPR) effect and is cited as a method of passively targeting
therapeutics to cancer tumors [15]. Typical sizes of the endothelial fenestrations in tumors range
from 100 nm to about 1 um [1]. This increased permeability observed in cancer tissues allows
particles that are excluded from other tissues to enter the cancer tumor. The size of these gaps
and the ability of nano-sized particles to diffuse into the cancerous tissue is dependent on the
type of tumor, with most types allowing particles up to about 500 nm to pass through [1]. Ideal
sizes for drug carriers to both pass through these fenestrations and accumulate in tissues in order
to take advantage of the EPR effect are believed to be between 100 nm and 300 nm [16]. After
penetrating into the tumor, particles between these sizes tend to accumulate due to the tumor’s
limited ability to recycle the extracellular fluid via the lymphatic system.

6

2.2 Ultrasound in drug and gene delivery
Ultrasound is defined as cyclic pressure waves with a frequency above 20 kHz [17].
These pressure waves are similar to those that create sound, but at this frequency they are beyond
the limit of human detection. Traditionally, ultrasound has been used in medicine for imaging
and for local heating of tissues. Recently it is being investigated for several beneficial roles that
it may play in therapeutic delivery systems. Beginning in the 1980’s, several studies reported
increased drug activity when drugs were administered along with the application of ultrasound,
particularly for cytotoxic drugs and chemicals [18, 19]. For example, Saad and Hahn exposed
HA1 chinese hamster cells to the cytotoxic drug Doxorubicin (Dox) with and without ultrasound
[18]. The fraction of cells that survived dropped by an order of magnitude with the application
of ultrasound compared to negative controls. For some time it was debated whether this effect
was a result of local hyperthermia or mechanically increased cell permeability.
By the 1990’s, it was believed that mechanical effects were responsible for increased cell
permeability [19]. Tachibana et al. reported that low intensity ultrasound increased drug activity
in HL-60 cells. These results suggested that mechanical effects were responsible for the drug
effect because thermal effects of this low intensity ultrasound would be minimal. Furthermore,
directly after ultrasound treatment, some of the cells were fixed for electron microscopy,
providing images that showed evidence of mechanical disruption on cell surfaces. Huber, et al.
showed that transfection of reporter DNA plasmids was drastically increased in vitro and in vivo
with the application of ultrasound, concluding that the cell membrane had to have been disrupted
to allow the plasmids into the cell [20].
Over the past decade, many studies have sought to better understand the mechanisms by
which ultrasound increases membrane permeability.
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Although the mechanism is still not

completely clear, the current hypothesis is that ultrasound causes cavitation events which
mechanically disrupt the cell membrane [7]. Cavitation is the formation and/or cyclic oscillation
of a bubble entrained in liquid [17]. These oscillations are created by the cyclic pressure changes
imposed by ultrasound. Beyond a threshold in negative pressure amplitude, these oscillations
become erratic and eventually result in the collapse of the bubble, creating a shock wave. This is
known as collapse cavitation. Furthermore, if the bubble is close to a surface, the asymmetric
collapse of the bubble can result in the formation of a high-velocity jet of liquid [21]. These
bubble oscillations, liquid jets, and shock waves generated with ultrasound can shear and
penetrate the cell membrane, creating reversible openings through which drugs or DNA plasmids
can pass [5, 7, 17, 19, 22-25]. Because of challenges in comparing the biological effects of
ultrasound at different frequencies, the mechanical index (MI) was developed to create a
normalized parameter for predicting the likelihood of cavitation at a given frequency. MI is
defined as:

𝑀𝐼 =

𝑃𝑟𝑎𝑟𝑒𝑓𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 ⁄ 106 𝑃𝑎
�𝑓 ⁄ 106 𝐻𝑧

(1)

where Prarefactional is the peak rarefactional (negative) pressure and f is the ultrasound frequency.
To investigate this mechanism, Schlicher, et al. exposed DU 145 prostate-cancer cells to
24-kHz ultrasound in the presence of calcein, a fluorescent marker molecule that does not cross
biological membranes [25]. After sonication, samples were given 5 to 10 minutes to recover.
The cells were then washed to remove non-incorporated calcein. Flow cytometry was used to
observe fluorescence of the cells from sonicated and non-sonicated experiments. Non-sonicated
cells did not fluoresce significantly. Increased fluorescence was observed in 10% to 40% of
sonicated cells, indicative of increased membrane permeability to the calcein. Furthermore,
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cellular response in the sonicated samples was characteristic of membrane wounding and repair.
At 500 kHz, permeabilization of the membrane occurs to some extent at a peak negative pressure
of 0.6 MPa [26]. The amount of calcein that was able to pass through the membrane increased
with peak negative pressure, but cell viability decreased rapidly at pressures above 1.6 MPa. The
amount of calcein taken up by the cells was correlated with the total ultrasound energy to which
they were exposed [26, 27].

Guzman, et al. performed similar experiments with fluorescent

dextrans of larger sizes and reported that larger molecules (464 kDa dextran) were also able to
diffuse into the cell cytosol [27]. However, these larger molecules were unable to enter the cell
nucleus, while calcein was able to do so.
Recently, advanced microscopy techniques have allowed researchers to observe holes
and tears in the cell membrane as well as subsequent membrane repair. For example, Schlicher
et al. used electron microscopy to observe changes in cell membranes after ultrasound exposure
including possible holes and interior vesicle fusion to patch these holes [25]. Prentice, et al.
visualized cavitating bubbles using optical microscopy. Afterwards, actual holes in the cell
membrane were observed using atomic force microscopy (AFM) [24].

These findings are

consistent with the hypothesis of reversible membrane damage caused by cavitation events that
open up holes in the membrane followed by self-healing.
Another important application of ultrasound in targeted drug and gene delivery is its
ability to initiate the release of drugs or genes from particles that sequester or bind the
therapeutics.

The same physical effects of ultrasound that increase permeability of cell

membranes can be advantageously used to release loaded drugs or genes from particles such as
micelles, microbubbles, and liposomes.

Polymeric micelles have been investigated as

ultrasonically activated drug carriers because of their ability to sequester hydrophobic drugs. For
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example, Rapoport, et al. and Husseini, et al. showed that Pluronic™ micelles could be used to
sequester Doxorubicin. The drug was released from the micelles in response to ultrasound
exposure at frequencies ranging from 20 kHz to 1 MHz and re-sequestered after insonation [9,
28]. This would allow a chemotherapeutic drug to be sequestered from interaction with the body
except where ultrasound is used to rupture the micelles and release the drug.

2.3 Microbubbles
Microbubbles are 1-10 µm-sized gas bubbles. The pressure inside of a spherical bubble
is proportional to the interfacial energy and inversely proportional to the radius. Therefore, the
formation of micro-scaled gas bubbles leads to high pressure gas inside of a microbubble – as
bubble size approaches 1 µm the Laplace pressure can be well over 1 atm [29]. Without being
somehow stabilized, this gas will quickly dissolve into the surrounding liquid [30].
Microbubbles for medical purposes are stabilized by a surfactant. Surfactants have polar and
non-polar regions and associate with the liquid-gas interface to lower the interfacial energy and
thereby lower the internal pressure of the bubble.

This makes it possible to form stable

microbubbles. To increase their lifespan, microbubbles are often formed from gases that have
low solubilities in water such as perfluorocarbons [31, 32]. These microbubbles are used as
contrast agents in ultrasound imaging of blood to increase the quality and sharpness of
ultrasound images [31].
There is potential benefit from applying microbubbles to targeted gene and drug delivery.
They can be used to lower the threshold pressures necessary for cavitation because they
introduce cavitation nucleation sites [33].

One study reported that the ultrasonic pressure

threshold for collapse cavitation at 757 kHz was 1.96 MPa in pure water [34]. This threshold
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was reduced to 0.53 MPa when microbubbles were introduced as cavitation nuclei. Bubbles
could therefore enhance cavitation and simultaneously act as drug carriers. Several types of
microbubbles have been investigated for use in drug and gene delivery.

Most notably,

perfluorocarbon gas bubbles are stabilized by an albumin shell (Optison) [22] or by lipid
surfactants (Definity) [5]. Both Optison and Definity have been shown to undergo collapse
cavitation when ultrasound was applied, resulting in increased gene transfection. Prentice et al.
sonicated a monolayer of cells in the presence of Optison™ microbubbles with a 1-MHz
transducer. An ultra-high-speed camera and atomic force microscopy were used to observe the
bubbles and the cell surface [24]. Bubbles could be observed oscillating, forming microjets, and
collapsing.
Bubbles can be used in drug delivery in a number of ways. Treat et al. used Optison
microbubbles to aid in delivery of Dox to the brain by increasing the permeability of the bloodbrain barrier [35]. Dox is a reasonable candidate for treatment of brain tumors, but normally
cannot pass through the blood brain barrier. Dox and Optison were co-administered to rats.
When ultrasound was applied, therapeutic concentrations of Dox were observed in the brain.
The delivered dose of Dox was dependent on the concentration of Optison and the intensity of
ultrasound.
Tinkov et al. describe the incorporation of drugs into the surfactant shell or attached to
the surface of a microbubble through covalent or non-covalent interactions.

Unger et al.

sequestered sudan black dye in the surfactant layer of microbubbles and showed that ultrasound
caused destruction of the microbubbles and release of sudan black [36]. Later, Paclitaxel, a
chemotherapeutic drug, was sequestered inside of the hydrophobic surfactant shell of 3 µm
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microbubbles and released with ultrasound.

Without ultrasound, the Paclitaxel remained

encapsulated.
Microbubbles have also been used to increase gene transfection into cells [23]. DNA
plasmids can be bound to the bubble surface or encapsulated inside [31]. Upon insonation, the
microbubbles undergo cavitation events that both aid in cellular transfection and release the
DNA from the bubble. Lawrie et al. used naked DNA plasmids coding for luciferase to measure
gene transfection into smooth muscle cells. Cells were exposed to a DNA-plasmid solution and
956-kHz ultrasound for 60 seconds [22]. Ultrasound alone produced a 16-fold increase in
luciferase expression relative to control experiments. When Optison microbubbles were present,
luciferase expression was increased by 300 times.
Using a surfactant that carries a positive charge on the surface attracts the negatively
charged DNA plasmids to the surface of the bubble [37-39]. Zobel et al. showed that the DNA
molecules are absorbed onto the surface of cationic particles [39]. This could result in a more
efficient treatment from a smaller dose of DNA. Anwer et al. attempted to transfect tumors on
mice with CAT reporter genes. It had previously been noted that these genes were transfected
into tumor cells, but a significant amount of CAT was also expressed in the lungs [37]. At low
DNA doses, using a positively charged stabilized bubble to deliver the gene resulted in a 270fold increase in tumor transfection over control experiments. Transfection into the lung was
unaltered compared to other treatments at this low dose. Therefore, using the cationic carrier
with ultrasound allowed a smaller DNA dose to have a large effect on the tumor while
transfection into other organs was limited due to the small dose that was necessary.
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2.4 Nanoemulsions
One disadvantage of microbubbles is that although they are small enough to pass through
capillaries, they are too large to pass through gaps in the endothelium, even in cancerous tissues.
Even with surfactants to lower the interfacial energy, bubbles do not persist at sizes much
smaller than 1 micron. This limits their ability to deliver therapeutics deep within tissues or to be
endocytosed into most types of cells. Because stable microbubbles are very difficult to form at
these sizes they are poor candidates for intra-tissue targeting via the EPR effect.
A potential nano-sized particle that can take advantage of the EPR effect while retaining
the ultrasound sensitivity of microbubbles is a nanoemulsion droplet. An emulsion is a mixture
of immiscible liquids. Small droplets of one liquid, referred to as the dispersed phase, are
suspended within the other liquid phase, referred to as the continuous phase. In the case of a
nanoemulsion, these droplets are less than a micron in diameter. In order to prevent phase
separation or droplet coalescence, the droplets are stabilized by surfactants similar to those used
to stabilize microbubbles. These surfactant molecules lower the interfacial energy between the
two phases and help to stabilize the nano-sized droplets. The surfactant may also create a
repulsive boundary, preventing the liquid droplets from colliding and coalescing. Oil in water
nanoemulsions are typically formed from non-polar liquids having low water solubility to
decrease their rate of dissolution.
Surfactants that have been used to stabilize emulsions for medical applications include
proteins, lipids, polymers, and traditional surfactants [40, 41]. Perfluorocarbon emulsions have
been used previously as artificial oxygen carriers and as ultrasound contrast agents for imaging
[42, 43]. More recently, emulsions have received attention as drug carriers [44-46]. Most
perfluorocarbon emulsions that have been produced previously were larger than 300 nm. Much
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of the current interest in perfluorocarbon nanoemulsions centers on the ability to vaporize
emulsion droplets with heat or acoustic energy. Such a technique would require emulsion
droplets to be formed from a liquid with a high vapor pressure. The leading candidates are
perfluorocarbons due to their high vapor pressure, low water solubility, and low toxicity [47-51].
Because stable emulsions can be formed on the nano-scale, the emulsion droplets could passively
target tumors by taking advantage of the EPR effect.

After reaching the target site,

nanoemulsions could be transformed into cavitating microbubbles, thus overcoming some of the
challenges of microbubbles and ultrasound-induced drug delivery while retaining many of the
advantages of these methods [52].
Giesecke et al. measured cavitation thresholds for various perfluorocarbon emulsions to
show that the droplets could be vaporized and that the resulting bubbles would cavitate [53].
Perfluoropentane, perfluorohexane and perfluoromethylcyclohexane emulsions were stabilized
with albumin and threshold negative pressures for collapse cavitation were determined by
observing a jump in broadband noise. The threshold negative pressure for collapse cavitation
was reported to be approximately 0.7 MPa at 0.74 MHz and 1.75 MPa at 3.3 MHz. At high
frequency, this threshold was comparable to the cavitation threshold for Optison, a commercial
microbubble formulation. This work showed that emulsion droplets can be readily vaporized in
an ultrasound field and that the threshold for observing cavitation from these vaporizing
emulsions was much lower than the cavitation threshold in pure water.
There are a number of parameters that effect droplet vaporization. Shiraishi formed
similar

emulsion

droplets

for

vaporization

with

mixtures

of perfluorohexane

and

perfluoropentane [54]. It was reported that these mixtures allowed the emulsion to persist above
the boiling temperature of perfluoropentane. These emulsions were prepared by sonication
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rather than high-speed shaking or high pressure emulsification used previously. Sonication
resulted in emulsion diameters that were as small as or smaller than these other methods while
maintaining a higher final concentration of perfluoropentane. These emulsions were stabilized
with block copolymers. In contrast to other polymer-stabilized drug carriers, the characteristics
of the polymer did not have a large effect on the pharmacokinetics of the emulsion. Kawabata,
et al. demonstrated that the threshold value for vaporization of emulsion droplets is dependent on
liquid used to form the emulsion droplets [55]. Perfluorocarbons with higher boiling points had
higher amplitude thresholds for ultrasonic vaporization. Furthermore, the acoustic threshold for
vaporization of an emulsion was tuned and controlled by mixing perfluorocarbons with different
boiling points.

Fabiilli, et al. demonstrated that emulsion droplet size had an effect on

vaporization [44]. Emulsions were prepared from perfluoropentane and stabilized with albumin.
In droplets with diameters less than 2.5 um, the acoustic threshold for vaporization increased as
droplet diameter decreased. Sheeran et al. have recently provided further insight to the effect of
diameter on droplet formation and vaporization. Nanoemulsions were formed by condensing
perfluorobutane with phospholipids as a stabilizing surfactant [56]. The resulting emulsions
showed the potential to remain stable and persist in solution at 37°C for hours despite
perfluorobutane having a boiling point of -1.7°C.

These metastable emulsion droplets also

showed the potential to vaporize back into gas droplets with the application of ultrasound [57].
Similar emulsions were formed with perfluoropropane, although they did not demonstrate the
same stability or ability to persist in solution even at 22°C.
Rapoport et al. used a polymer-stabilized perfluoropentane emulsion to deliver Dox to
tumors in mice [58, 59]. It was reported that Dox was sequestered inside polymer micelles as
well as carried with the emulsion droplets. First, heating was used to show that the droplets
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could be vaporized into micrometer-sized bubbles. This was visualized under a microscope.
Ultrasound was then used to deliver Dox to tumor cells. Cells exposed to this treatment in vitro
showed a higher uptake of Dox compared to negative controls. In vivo, tumors treated with
ultrasound did not continue to grow while negative control tumors did grow. Later, this group
used perfluoro-15-crown-5-ether (PFCE) to form emulsion droplets stabilized with block
copolymers [45]. There was evidence of vaporization of droplets despite the much higher
boiling point of PFCE (146°C). While the droplets did vaporize, they did not undergo collapse
cavitation. Furthermore, there was evidence that the droplets re-condensed after ultrasound
exposure. In contrast, perfluoropentane (PFC5) droplets went through an irreversible phase
change and collapse cavitation was detected from the resulting gas bubbles [59]. Droplets were
loaded with Paclitaxel and both PFCE and PFC5 emulsions were effective in reducing tumor size
when ultrasound was applied [45, 59, 60].
Liquid emulsion droplets have also recently received attention as ultrasound contrast
agents due to their echogenicity, and have been used to enhance ultrasonic imaging of
vasculature and tissues [61]. Combining their drug carrying potential with their potential in
ultrasound or MRI imaging has led to nanoemulsions sometimes being called “theranostics.” In
vivo studies have already demonstrated that the drug delivery potential and echogenicity of
nanoemulsions can be taken advantage of simultaneously, using emulsions to deliver drugs to a
target location while simultaneously imaging the target area and/or the location of the drugs [45].
While emulsion droplets have begun to receive attention as drug-carrying particles, the
amount of drug that can be encapsulated is a potential problem. Even hydrophobic drugs tend to
accumulate in the surfactant shell rather than in the hydrocarbon phase [60]. The low volume of
this shell would limit the amount of drug encapsulated. Dual phase emulsions seem to be
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required in order to encapsulate and carry significant amount of drug; emulsions are formed with
a perfluorocarbon layer and an oil layer in order to increase encapsulated drug and maintain
droplet stability [44, 62]. These emulsions retain the ability to vaporize due to the inclusion of a
perfluorocarbon phase, but can also carry increased amounts of drug in the oil phase. However,
the threshold for vaporization is increased by the presence of an oil phase [44].
Despite these drawbacks and even though emulsion droplets are less responsive to
ultrasound than microbubbles, the combination of ultrasound responsiveness with the potential to
persist at nano-scale sizes make them exciting potential drug carriers for ultrasound targeting.
The droplets can permeate deep into tissues, followed by activation by ultrasound that could both
deliver their drug load and increase cell permeability. It is possible that they could even be
endocytosed, and then be excited by ultrasound to create bubbles [46]. This could potentially
target drug release not just to within a target tissue, but within targeted cells

2.5 Liposomes
Liposomes are another drug carrier of interest. A liposome is a small spherical vesicle
made up of a phospholipid bilayer enclosing a volume of aqueous liquid [63]. These lipid
vesicles have been studied for several decades for a variety of uses in medicine, chemistry and
biology. They are formed by dissolving phospholipids in an aqueous environment. The strong
interactions of the non-polar lipid tails drive the spontaneous formation of spherical bilayer
membranes and vesicles [63]. The shape and size of these vesicles can then be altered by freeze
thawing, exposure to ultrasound, or by extrusion through membranes.

Over the past decade

liposomes have been investigated as drug carriers in a wide variety of applications, including
transdermal delivery and intravenous delivery of a wide range of therapeutics [63].
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After

liposomes reach their target site, release of the drug can be triggered by pH changes, degradation
of the liposome by lipases, or simply by slow diffusion through the membrane. In order to
increase circulation time in the body, liposomes are often formulated with a small amount of
lipid that has polyethylene glycol (PEG) attached to the head groups [64]. The “PEGylation” of
the liposomes prevents plasma proteins from binding and subsequent phagocytic recognition and
removal of the liposomes [65].
A significant advantage of liposomes is that they can be formed and remain stable at very
small (nanometer) sizes. For this reason, they have recently been investigated for use in cancer
therapies due to their ability to extravasate via the EPR effect [66, 67]. The EPR effect leads to a
high concentration of liposomes in cancerous tissues. When the EPR effect is combined with the
high circulation times of PEGylated liposomes, drug delivery to cancerous tumors is
significantly enhanced compared to other treatments.

For example, Gabizon et al. used

PEGylated liposomes to increase the circulation time of Doxorubicin-carrying liposomes [68].
The longer circulation time, together with the EPR effect, led to a 4 to16-fold increase of drug
concentration in the tumor compared to free drug delivery techniques. When compared to nonPEGylated liposomes, these long-circulating liposomes were less toxic and demonstrated less
accumulation in the liver, a typical accumulation site for standard liposomes.
Liposomes have also been investigated for gene delivery. In such an application, the
liposome is usually formed from cationic lipids that will interact with DNA, attracting the
negatively-charged DNA to their surface [67]. Koch, et al. formed liposomes using lipids with
cationic head groups [69]. These cationic liposomes were incubated with plasmid DNA coding
for green fluorescent protein (GFP) to allow the DNA to condense to the outside of the
liposomes. Cells were exposed to ultrasound in the presence of these DNA-liposome complexes,
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resulting in a significant increase in GFP expression compared to non-sonicated samples.
Similarly, polycationic molecules have been complexed with DNA and then encapsulated in
liposomes [70]. These liposomes demonstrated an increased ability deliver genetic material to
cells compared to the polycation-DNA complexes alone. However, these cationic materials both polycations and cationic lipids - are typically toxic and the increased toxicity may outweigh
their benefits as gene-delivery vectors.
Liposomes have many advantages as drug carriers, including their versatility,
biocompatibility, and biodegradability. The lipids that are used to form the liposomes can be
custom tailored for a specific application to control the surface charge, chemical properties,
rigidity, and stability of the liposome. Furthermore, the hydrophilic interior of the liposome can
enclose hydrophilic drugs, while either the non-polar membrane or enclosed micelles or
nanoemulsions can sequester hydrophobic drugs.

Liposomes have shown the ability to

effectively sequester drugs and the ability to release these drugs [71].

Usually, drugs are

released from liposomes by allowing diffusion through the membrane or allowing the liposome
to be degraded with time [72]. Drug release from liposomes largely depends on the lipid
composition of the membrane and its stability. Inclusion of polyethylene (PEG) on the surface
of the liposome has been shown to greatly increase the time that the liposomes remain in the
body compared to non-PEGylated liposomes or free drug [66, 71]. Another key characteristic of
liposomes is the ability to control their size [73], which allows them to be used for “passive”
targeting to cancerous tumors via the EPR [74]. This ability to take advantage of the EPR is the
most often quoted advantage of liposomes for targeted drug delivery; liposomes are formed at
small sizes that allow them to accumulate in tumors, followed by drug release over time as the
liposome degrades or as drug diffuses out.

19

A variety of release strategies have been investigated to further target drug delivery from
liposomes and increase their efficiency. Liposomes have been designed with pH-sensitive lipids
so that they will open up and release their drug load in an acidic environment [75] as well as with
temperature sensitive chemistries so that hyperthermic temperatures can induce release [76, 77].
Liposomes have also been designed to be sensitive to specific enzymes in order to target and
control drug delivery [78]. Light has also been explored as a method of releasing contents from
liposomes [79]. These techniques have yielded mixed results and have a variety of advantages
and disadvantages. Because of its non-invasive nature and ability to control both the location
and time of release, ultrasound may prove to be a particularly advantageous method for targeting
drug delivery from liposomes. Using this method would allow liposomes to accumulate in
tissues, followed by release of the sequestered contents with ultrasound. Because of these
advantages, ultrasound-sensitive liposomes have recently received a significant amount of
research attention.
One potential problem with using ultrasound to release contents from liposomes is that,
unlike microbubbles, they do not inherently respond to ultrasound.

Many of the studies

investigating ultrasound triggered release have employed high intensities of ultrasound and/or
long exposure times. Chen and Wu sonicated nano-scale liposomes with continuous wave 900
W/cm2 ultrasound at 1.1 MHz [80]. Only 21% of the encapsulated material was released after 10
seconds of ultrasound exposure and only 70% was release after 60 seconds despite the high
intensity being applied. As a point of reference, these ultrasound parameters would result in a
mechanical index of almost 5. Mechanical indices above 1.9 are not permitted by the FDA for
medical applications and diagnostic ultrasound is typically operated at mechanical index values
closer to 1. Similarly, Klibanov et al. used short exposures of very intense ultrasound (7 MPa

20

peak acoustic pressure) to release contents from a liposomal carrier [81]. Despite the intensity of
ultrasound only 11-30% of the entrapped material was released.
In addition to high intensities, long exposure times of lower intensity ultrasound have
been investigated. For example, Evjen, et al. reported 10% release from conventional PC-based
liposomes after 6 minutes of exposure to 40-kHz ultrasound at approximately 2 W/cm2 (MI =
1.2) [82]. Schroeder, et al. demonstrated 50% and higher release from liposomes exposed to 3.3
W/cm2 (MI = 2.2) ultrasound at 20 kHz for 1 to 3 minutes [83]. This group also was able to
make a connection between liposomal release and cavitation. Below cavitation thresholds,
increases in liposomal release were modest, whereas above cavitation thresholds, increases in
liposomal release became much more pronounced. It is believed that in order for conventional
liposomes to be induced to release their contents with ultrasound, bubbles must nucleate, cavitate
and create mechanical shear that disrupts the bilayer membrane of the liposomes [84-87]. This
dependence on cavitation has several drawbacks. The high intensities of ultrasound that can be
required may damage cells. Furthermore, there is a lack of cavitation nuclei within tissues and
even in the blood. Therefore, the dependence on cavitation nuclei may limit the ability of
ultrasound to disrupt liposomes deep within tissues, where delivery would be most useful.
There are also other parameters that have an effect on ultrasound-induced release from
liposomes. Pong, et al. demonstrated that the size of the liposomes has a significant effect [88].
Liposomes were formed at several sizes and exposed to ultrasound.

One-µm vesicles

demonstrated 30% release of encapsulated contents after 100 minutes of 1-MHz ultrasound
exposure at approximately 7.5 W/cm2 with a duty cycle of 0.4. 300-nm vesicles demonstrated
20% release after the same amount of exposure and 100-nm vesicles demonstrated almost no
release. It has also been shown that the inclusion of PEG-lipids in the membrane increases its
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susceptibility to ultrasound [88-90].

More recently, it has been demonstrated that lipid

composition has a significant effect on ultrasound mediated-release from liposomes [82, 91-93].
Evjen, et al. compared the release from conventional PC- based liposomes to liposomes
containing DOPE or DSPE as their principle constituents [82]. At long exposure times DSPE
liposomes demonstrated as much as 5 times more release than phosphocholine based liposomes,
and DOPE released 9 times as much. In 20% serum the ultrasound sensitivity of all three
formulations was greatly reduced, with only DOPE still releasing a significant amount of drug.
Small, et al. similarly investigated the effect of membrane composition on ultrasound-mediated
release from liposomes containing various mixtures of DOPE, DPPC and cholesterol [93]. As
the concentration of DOPE was increased, the amount of release caused by ultrasound also
increased. Increasing the amount of cholesterol decreased the amount of release. Another
parameter that has an effect on liposomal release is the frequency of ultrasound applied. It has
been shown that lower frequencies of ultrasound release more of the encapsulated materials from
liposomes than do high frequencies [88, 92].
While studies have shown that liposomes can be induced to release their contents with
ultrasound, the ultrasound parameters required to do so typically require long times and/or high
intensities. These parameters can lead to unwanted heating and cell death in healthy tissues. In
order to avoid these negative effects, liposomes have been modified to attempt to increase their
ultrasound susceptibility while retaining their versatility and ability to deliver drugs. Klibanov,
et al. attached small liposomes to microbubbles to increase ultrasound sensitivity [81]. This
increased sonosensitivity, but resulted in large complexes and limited the versatility of the
liposome. Other groups have also developed liposomes that either encapsulate small bubbles
[94] or contain more air than conventional liposomes [95, 96]. These “bubble liposomes” or
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“acoustically active liposomes” demonstrate increased release of encapsulated contents
compared to conventional liposomes. They have also been used to simultaneously deliver
therapeutics and enhance diagnostic imaging, a field that has become known as theranostics.
These acoustically active liposomes, however, are typically quite large.

While they have

significant advantages in combining therapeutics and diagnostics, they cannot take advantage of
the EPR effect and would not be internalized into cells.

Lastly, increased sensitivity to

ultrasound has been achieved by varying the lipid compositions. Liposomes without cholesterol
tend to be more susceptible to ultrasound and PEGylated lipids increase sonosensitivity [89, 90].
Replacing conventional phosphocholines with other lipids can also increase sonosensitivity [82,
91-93]. These liposomes, however, are typically more susceptible to ultrasound due to increased
membrane permeability and loss of stability that may limit the liposomes’ ability to carry and
sequester drugs efficiently.

2.6 Liposomal encapsulation
There are a number of techniques that are commonly used to encapsulate materials inside
of liposomes.

These techniques include passive diffusive, reverse phase evaporation,

dehydration–rehydration of preformed empty liposomes, freeze–thaw cycling and pH induced
loading [97]. While these common loading techniques typically encapsulate small molecules, it
is an additional challenge to encapsulate relatively large emulsion droplets inside of lipid
vesicles. One technique that has been used to encapsulate relatively large particles inside of
liposomes is sheet formation and refolding [98]. This technique takes advantage of an ethanolinduced phase transition to an interdigitated lipid phase. The addition of short chain alcohols to
the liposome suspension causes swelling and separation of head groups as the alcohol interacts
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with the polar region of the membrane [99]. As the head groups swell and the distance between
lipids increases, the tail groups from opposite sides of the membrane interdigitate, thinning and
stiffening the membrane. As the membrane becomes more rigid, its ability to curve into a
spherical shape is reduced and liposomes with a higher curvature unfold and fuse into sheets
[100].

This transition is observed even at temperatures below the lipid melting transition

temperature (Tm) [98]. These sheets remain stable even after the removal of the alcohol if
temperature is maintained below the Tm due to the inability of the lipids to move and flow at
these temperatures. However, if the temperature is increased above the Tm in the absence of
alcohol, the sheets refold into closed vesicles [101]. When the sheets refold into spherical
vesicles, even relatively large particles in the solution adjacent to the sheet will be encapsulated
inside the newly reformed liposomes. Boyer et al. used this technique to encapsulate small
liposomes inside of larger lipid vesicles [102]. Drug was encapsulated in the smaller, inner
vesicles.

Release of the drug, therefore, required either the gradual breakdown of two

membranes or the diffusion of encapsulated drugs through these two membranes for drug
release. It was shown that this double encapsulation resulted in a more gradual and sustained
release of drug than from conventional single layer liposomes.

2.7 Endocytosis and endosomes
Endocytosis is a process by which many large external molecules, such as proteins and
nutrients are engulfed into most living cells. This pathway is commonly used to internalize large
molecules or polar molecules that could not otherwise pass through the non-polar interior of the
cell membrane bilayer. Depending on the specific situation, including cell type and specific
pathway, there can be a wide range of sizes and amount of material endocytosed. Chithrani et al.
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used transferrin-coated gold particles with HeLa cells to study clathrin-mediated endocytotic
mechanisms in this cell line [103]. It was reported that particles up to 50 nm were endocytosed,
but as particle size increased the rate and amount of endocytosis decreased. Rejman et al.
studied caveolin-mediated endocytosis in murine B16 cells [104]. Cells were exposed to 50,
100, 200, 500, and 1000 nm latex beads. The rate of endocytosis decreased as the particle size
increased, with the smaller sizes of beads being endocytosed by 30 minutes. Endocytosis of the
500 nm beads was detected only after 2-3 hours, and microscopy revealed that although inside
the cell, these beads could not penetrate deep-into the cytoplasm. In this study, 1000-nm beads
were not endocytosed. Other cell lines, especially fibroblasts and macrophages, have been
shown to endocytose or phagocytose particles larger than 1 µm [105, 106]. 3T3 cells may also
be candidates for endocytosis of particles up to 3 µm [106].
In all types of endocytosis, the cell membrane extends and surrounds a portion of external
media.

The membrane then comes together and pinches off to entrap previously external

molecules. The new interior vesicle is called an endosome [107]. After an endosome is formed,
the pH in this vesicle is lowered initially by actively pumping hydrogen ions inside to help break
down and digest newly endocytosed materials [108]. Later, these endosomes will typically fuse
with acidic lysosomes to complete digestion of their contents. To be effective, therapeutics that
require intracellular delivery, including genetic treatments and many drug therapies, usually must
escape from the endosome before they are degraded. Escaping from the endosome is one of the
major barriers to effective intracellular delivery.
Because endosomal escape remains a significant challenge for efficient drug delivery,
several techniques have been investigated in order to try to increase controllable and efficient
endosomal escape. These techniques include pH buffering, pore formation in the endosomal
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membrane, fusion with the endosomal membrane, and photochemical disruption of the
endosomal membrane.
In the pH buffering technique, or proton sponge effect, molecules with many amine
groups are employed. As the amine groups are protonated in the acidic environment of the
endosome, there is an influx of protons and other ions (e.g. chloride counter ions) into the
endosome, causing an osmotic imbalance. This osmotic imbalance causes the endosome to swell
and burst. For example polyethylenimine (PEI) has been investigated as a potential gene carrier
and has been shown to increase gene transfection [109]. As a result of this “proton sponge”
effect of PEI, it was found that acidification of the endosome is slowed, and more proton
pumping is required than usual to lower the pH. In this study, chloride ion concentration inside
the endosome also increased beyond normal levels. The osmotic pressure gradient increased as
the number of ions inside of the vesicle increased, causing the endosome to swell until it burst,
and its contents were released into the cytoplasm [110]. Because of the ability of the “proton
sponge” effect to produce escape from the endosome, this technique has received much attention.
However, although this technique has proven effective, molecules that are most efficient for the
proton sponge effect, such as PEI, are also typically toxic to cells.
Pores can be formed in the endosomal membrane with peptides that have high affinity for
the inside of the endosomal membrane [111]. Many of these peptides respond to low pH, which
induces a conformation change and insertion into the endosomal membrane. When the peptide is
inserted in the membrane it causes a pore to form, and the contents of the endosome are allowed
to leak out into the cytosol.
Another method described by Akita et al. employs fusogenic delivery vesicles [70].
After being encapsulated inside of the endosome, these vesicles fuse with the endosomal
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membrane, releasing their contents into the cytoplasm.

The fusogenic properties of these

proteins can be enhanced at low pH so that this release predominates from the endosome [112].
In another method, Fretz and coworkers used saporin-containing liposomes with
LumiTrans, a photosensitive agent that localizes to the endosome membrane [113].

Upon

illumination, these photosensitive agents generate reactive oxygen species that damage the
endosomal membrane, releasing the liposomes into the cytosol.
All of these techniques for endosomal escape have shown some promise. However, there
are a number of disadvantages. Many of these techniques involve polymeric materials that are
toxic, and most of these methods lack the ability to specifically control the location and rate of
release.

2.8 Summary
In summary, there are several techniques that have been investigated in order to enhance
targeted drug delivery. These techniques can be classified as either active, passive, or actuated.
Active targeting typically refers to the use of chemical receptors, targets, or triggers to enhance
site specific delivery. Passive targeting takes advantage of inherent physical properties of a
particular tissue, such as a leaky vasculature, to preferentially deliver drugs. Actuated targeting
employs the use of an external trigger to release sequestered drugs from drug carriers at the
target site.

While all of these techniques have shown potential, they have a number of

shortcomings. A drug delivery system may be made more efficient by combining several
techniques.
The acoustic vaporization of emulsion droplets makes them interesting candidates for
employing several targeting strategies simultaneously. The emulsion droplets may act as drug
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carriers or may provide an ultrasound sensitive component to other drug delivery systems.
Specifically, the goal of this project was to develop a liposomal drug delivery system that would
be more useful for actuated targeting. Liposomes are often cited as being very versatile and
useful drug carriers; the ability to control the size of the liposomes and functionalize their surface
allows them to employ both active and passive drug targeting strategies. When liposomes
combine these techniques, their drug-delivery efficiency is increased. However, once liposomes
have accumulated at a target site, drug delivery can be dependent on the slow processes of
liposomal degradation and/or diffusion of drug out of the liposomes.

Liposomes are not

inherently responsive to ultrasound. The goal of this research was to explore the potential of
using emulsion droplets and liposomes in combination to add an ultrasound sensitive element to
the liposomes. The potential of these expanding emulsion droplets to aid in endosomal escape
was also explored.
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3

OBJECTIVES

The overall objective of this research was to develop a system for gene and drug delivery
from nano-scale sized drug carriers that can be triggered by ultrasound, leading to liposomal and
possibly endosomal rupture. This will allow treatment to be targeted to a specific area by
ultrasound and could provide a new non-toxic method for endosomal escape. The proposed
method to add ultrasound sensitivity to the drug carriers is acoustically-induced vaporization of
high-vapor-pressure emulsion droplets. The drug carriers that were considered include emulsion
droplets as well as combinations of emulsion droplets and liposomes. In order to be effective,
the drug carriers should have small enough diameters to be able to take advantage of the EPR
effect for anti-cancer applications. The specific goals of this research were:
I.

Form emulsion droplets with diameters between 50 – 150 nm. Characterize the droplets
and show the potential to vaporize these droplets using ultrasound.
1. Form perfluorocarbon emulsions using various surfactants and techniques, and
compare advantages and disadvantages of these various surfactants and techniques.
2. Determine size vs surfactant-to-PFC ratio for the various surfactants to minimize
droplet size. Control the size of the emulsion droplets down to 50 -150 nm.
3. Demonstrate that the emulsion droplets can be vaporized with the application of
ultrasound and determine vaporization threshold parameters.
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4. Explore the ability of vaporizing emulsions to aid in ultrasound-induced drug
release from conventional liposomes at low ultrasound intensities.
II.

Form and characterize eLiposomes.
1. Form and characterize liposomes with emulsion droplets encapsulated inside.
2. Explore the ability of these eLiposomes to sequester a model drug.
3. Explore ultrasound-mediated release of a sequestered model drug from these
eLiposomes upon vaporization of the emulsion droplets. Investigate the effect of
particle size, temperature and ultrasound parameters on drug release.

III.

Perform preliminary in vitro experiments on cells showing model drug release from
eLiposomes using ultrasound.
1. Investigate the ability of cells to endocytose eLiposomes and emulsions.
2. Explore the ability of emulsion droplets to aid in endosomal escape when exposed
to ultrasound.
3. Explore the ability of eLiposomes to deliver therapeutics to the cytosol of cells
when exposed to ultrasound.
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4

MATERIALS AND METHODS

4.1 Materials and equipment
4.1.1 Materials
Perfluoropentane (PFC5) was purchased from SynQuest Labs., Inc. (Alachua, FL).
Perfluorohexane (PFC6), and perfluoroheptane (PFC7) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). All perfluorocarbons were stored in a freezer until used. Phosphate buffered
saline (PBS) solution was purchased from Fisher Scientific (Fair Lawn, NJ). Sodium chloride
and dimethyl sulfoxide (DMSO) were purchased from Mallinckrodt (Paris, Kentucky). Sucrose
was purchased from Avantor Performance Materials (Phillipsburg, NJ) and glucose form United
Biochemical Corp. (Cleveland, OH). Dipalmitoylphosphatidylcholine (DPPC) in chloroform
and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene

glycol)-2000]

(DSPE-PEG2000-amine) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).
Zonyl® FSN-100 fluorosurfactant was a gift from DuPont. Perfluorooctanoic acid (PFOA), folic
Acid and N,N'-dicyclohexylcarbodiimide (DCC) were purchased from Sigma-Aldrich (St. Louis,
MO).
Gibco DMEM media, F-12 Nutrient Mixture, RPMI-1640 folate free media, and Fetal
Bovine Serum were purchased from Life Technologies (Grand Island, NY). Trypsin for cell
passaging was purchased from Invitrogen (San Diego, CA). LysoTracker Red was purchased
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from Molecular Probes (Eugene, OR). Calcein was purchased from MP Biomedicals (Solon
Ohio, USA).
All water used was double distilled. Calcein was dissolved in water by slowly adding
NaOH to raise the pH until the color of the solution changed from light orange and cloudy to a
deep red, indicating dissolution. Additional water was added to the solution to dilute the calcein
concentration to 30 mM. Chloroform was evaporated away from the DPPC using a Rotovap,
and DPPC-in-water solutions were prepared at 30 mg/mL by film hydration. Water used in
acoustic measurements was de-gassed prior to experiments by boiling the water and exposing it
to low pressure in a vacuum oven.

4.1.2 Ultrasound equipment
A 3-mm-diameter 20-kHz ultrasound probe driven by a Vibra-Cell VCX400 (Sonics and
Materials, Newton, CT) was used to form and shear emulsion and liposomes samples. This same
probe setup was used to perform 20-kHz release experiments.

Ultrasound intensity was

previously calibrated in degassed and deionized water using a low frequency hydrophone (Model
8103, Bruel & Kjaer, Naerum, Denmark). For this calibration, the hydrophone was positioned 3
mm from the transducer and connected to an oscilloscope. The hydrophone voltage signal was
converted into intensity (W/cm2) values using the factory calibration parameters.
525 kHz experiments were performed with a focused transducer (Sonic Concepts,
Woodinville, WA). The signal was generated with an HP 33120A waveform generator and
amplified with an Electronics and Innovation power amplifier (model 2100L). The amplified
signal was passed through an external switch, an oscilloscope (Tektronix TDS 2014), and a
matching network prior to the transducer. A needle hydrophone (HNR-1000, ONDA Corp.,
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Sunnyvale, CA) had been used previously to determine the location of the focus of the transducer
and to create an intensity calibration at the focal point. The same hydrophone and oscilloscope
were used to collect acoustic emissions from emulsion samples.

4.1.3 Dynamic light scattering
Particle sizes of emulsions, liposomes and eLiposomes were determined by dynamic light
scattering (DLS) using a Brookhaven 90Plus Particle Sizer (Brookhaven Instruments Co.,
Holtsville, New York). Samples were prepared at concentrations to give 800 kcounts/second to
1.2 Mcounts/second. Ten experimental runs of 1 minute each were performed on each sample
and averaged.

4.1.4 TEM microscopy
Samples were viewed and imaged using several TEM techniques. Samples were viewed
by negative staining on an FEI Tecnai 12 transmission electron microscope (Hillsboro, Oregon,
USA) on continuous carbon grids using a Gatan single-tilt sample holder.

Samples were

prepared for cryoTEM on 200-mesh copper (holey-carbon) grids. Grids were plunge frozen in
liquid ethane using a FEI Vitrobot. The samples were then viewed on an FEI Tecnai F30
transmission electron microscope (Hillsboro, Oregon, USA) using a Gatan 626 cryoholder.
Negative staining and cryoTEM images were recorded on Gatan 1024 × 1024 CCD cameras.

4.1.5 Fluorometry
A QuantaMaster fluorometer (Photon Technology International, Birmingham, New
Jersey) was used for calcein release experiments. The excitation and emission wavelengths were
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set to 488 nm and 525 nm, respectively. The apertures were adjusted to limit the fluorescent
counts per second (cps) to less than 1,000,000 in order to avoid damaging the detector.
Experiments were typically run closer to 100,000 cps. Because the aperture openings were not
precise, they were adjusted only when necessary in order to remain consistent from one
experiment to the next. Data was collected at 4 points/second and exported to Microsoft Excel
for analysis.

4.1.6 Fluorescent and confocal microscopy
An Olympus IX70 microscope using a 40X objective microscope was used to view
emulsion samples before and after exposure to ultrasound. This microscope was also used for
initial experiments with cellular calcein delivery and fluorescence.

Intracellular uptake of

calcein into HeLa cells was verified using an Olympus FluoView FV300 confocal laser scanning
microscope. An argon laser with an excitation wavelength of 488 was used to visualize calcein
within the cells. A red helium-neon laser was used to view LysoTracker Red dye within the
cells.

4.2 Methods and procedures
4.2.1 Emulsion formation
Two different methods were used to form and stabilize perfluorocarbon emulsions with
PFC5 and PFC6: shaking and sonication. To form emulsions by shaking, the desired amount of
PFC, surfactant and water was added to a crimp-top vial. In order to exclude all air from the
vial, it was prepared in a water bath. The cap was carefully placed on top crimped while the vial
was submerged. In order to form the emulsion, the vial was then shaken on a COE Mix 5000
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High Speed Mixer (GC America Inc., Alsip, IL) at 4200 cycles per second for two 30-second
intervals.
Sonicated emulsion samples were prepared by adding the desired amount of PFC,
surfactant, and water to a plastic cuvette. Typically, 0.1 to 0.2 g of PFC was added along with
1.5 mL of water, while the amount of surfactant was varied. The sample was cooled on ice and
the 20-kHz ultrasound probe was inserted directly into the cuvette. The sample was sonicated
while still on ice for the desired amount of time.

Ultrasound parameters and the time of

sonication were varied. During the beginning of sonication, care was taken to move the probe tip
into the corners of the cuvette to ensure mixing and suspension of the PFC phase.
For experiments that required large emulsion droplets, low intensities (0.5 W/cm2) were
used and no further processing was required. Slightly higher intensities (1 W/cm2) were used to
form smaller emulsions. After nanoemulsion formation, droplet size of some samples was
further reduced by extrusion through a 100-nm or a 50-nm polycarbonate filter using an Avanti
Mini Extruder (Alabaster, AL, USA). The extrusion was carried out at 50°C by placing the
extrusion apparatus on a temperature controlled heating block for 10 minutes prior to extrusion.
After heating, the emulsion was passed through the filter 15 times. The syringes were removed
from the heating block and allowed to cool prior to removing the emulsion sample.

4.2.2 Verification of vaporization
Ultrasonic vaporization of emulsion droplets was verified by applying ultrasound to the
emulsion sandwiched between a microscope slide and cover slip at room temperature (24°C).
100 µL of emulsion was diluted in 1 mL of water. The diluted emulsion was viewed with an
Olympus IX70 microscope using a 40X objective. The slide was then inverted and exposed to 1
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W/cm2 ultrasound for 5 seconds by applying a small amount of ultrasound gel to the slide and
positioning the 20 kHz transducer directly into the gel. The slide was again imaged after
ultrasound exposure. Control experiments were performed using plain water and a DPPC lipid
solution to verify that bubbles were not formed in the absence of PFC emulsion.
This experiment was repeated at 37°C. Heating was performed in a 37°C incubator. In
order to test the amount of time required for heating, a thermocouple was used to measure the
temperature of the liquid film on the slide and a similar volume of water prior to experiments.
Slides were prepared with diluted emulsions and were viewed after preparation, followed by 5
minutes of heating in the incubator at 37°C. The samples were then removed from the incubator
and imaged quickly to observe any effects from heating. After heating again, ultrasound was
applied to the slide as described above and the slide was imaged again.
Vaporization of emulsion droplets was further verified by collecting the acoustic spectra
created by emulsion samples and controls when exposed to an ultrasonic field. Various acoustic
signatures have been correlated with cavitation of entrained bubbles. The acoustic signal can be
Fourier-transformed, with key peaks of the resulting spectra providing clues about what is
happening when emulsion droplets are exposed to an acoustic field. The applied frequency, f, is
expected to be the strongest peak on the spectrum. As the intensity is increased, peaks at higher
harmonic frequencies (2f, 3f, 4f...) and at the subharmonic (f/2) frequency have been linked to
stable cavitation [114-117]. Subharmonic frequencies and a non-frequency dependent increase
of broadband sound have been linked to collapse cavitation [21, 118, 119]. For this reason, the
emergence of harmonic peaks, subharmonic peaks, and a broadband baseline shift were
identified as phenomena of interest.

36

Control and emulsion samples were placed in the bulb tip of a transfer pipette. This bulb
was positioned in the focal point within the water bath on the 500 kHz insonation chamber. A
hydrophone was positioned at a 90 degree angle to the sample chamber about ½ an inch away.
The intensity of ultrasound was increased gradually while observing for the emergence of the
key spectral phenomena on an oscilloscope. Some samples were heated by circulating 37°C
water into the water bath with a Neslab RTE 110 temperature bath/circulator. Water was filtered
between the temperature controller and the water bath containing the transducer to minimalize
the introduction of bubbles into the bath.

4.2.3 Lipid sheet formation
DPPC liposomes were prepared using a standard film hydration technique.
Briefly, DPPC in chloroform was added to a round bottom flask. The solvent was removed under
vacuum with a rotary vacuum evaporator, leaving a thin dry lipid film on the flask. This film was
hydrated in water to a lipid concentration of 30 mg/mL. The mixture was heated to 60°C while
being stirred in the rotary evaporator for 10 minutes or until the majority of the lipid was
suspended. If necessary, the solution was re-pipetted and stirred again to suspend remaining
lipid. Small unilamellar vesicles (SUVs) were formed from the resulting lipid solution using two
methods: extrusion and sonication. For extrusion, the hydrated lipid solution was extruded 10
times through a 50-nm filter at 50°C using the Avanti Mini Extruder. Alternatively, SUVs were
also prepared by sonicating the 30 mg/mL DPPC solution at 1 W/cm2 for 15 minutes, or until the
color had changed to a translucent bluish. The sizes of the resulting SUVs were verified by DLS
before proceeding. If necessary, the solution was allowed to cool and was sonicated again.
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The resulting vesicles from both methods ranged in size from 30 to 80 nm in diameter as
measured by DLS. SUVs prepared by extrusion were typically larger (60-80 nm), but had a
narrower size distribution and less variability. Sonicated samples could be formed at smaller
diameters, with median sizes as small as 30 nm. However, sonicated samples typically had a
wider size distribution and median diameters were less consistent from one sample to the next.
Despite increased variability and typically broader size distributions, sonication was able to form
SUV’s of smaller sizes with more ease than extrusion and median sizes were never larger than 50
nm after two periods of sonication. Both sonication and extrusion proved effective in forming
small enough vesicles for sheet formation.
Interdigitated DPPC sheets were formed by adding ethanol dropwise to DPPC SUVs
while stirring. Ethanol was added to a total concentration of 3 M. As the ethanol was added, the
solution changed from translucent pale blue to opaque white and showed an increase in viscosity
as the SUVs opened into lipid sheets [98, 120].
The sheets were suspended and diluted in 50 mL of water at room temperature and
centrifuged at 1800 x g for 3 minutes, resulting in a large pellet of DPPC sheets. The alcoholrich supernatant was removed and the pellet was re-suspended in water and centrifuged again to
reduce the ethanol concentration to less than 10 mM. The pellet was again suspended in a small
volume of water in order to transfer the sheets to microcentrifuge tubes with 10 mg of DPPC
allotted to each tube. The extra water was removed through one more cycle of centrifugation. If
necessary, the interdigitated sheet phase was stored at 4°C. Lipid sheets remained stable for
several weeks if the temperature was maintained below the melting transition temperature (Tm)
for DPPC (41°C).
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4.2.4 eLiposome vesicle formation
eLiposomes were formed by adding 0.2 mL of PFC emulsion to the interdigitated sheets
along with 0.2 mL of water (for TEM imaging) or of a 30 mM calcein solution (for release
experiments). This solution was re-pipetted and briefly vortexed to ensure complete mixing of
the sheets and the emulsion droplets. The solution was then heated to 50°C and stirred with a
magnetic stir bar for 30 minutes, allowing the sheets to fold back into vesicles, trapping some
nanoemulsion droplets inside (see Figure 1). The resulting eLiposomes were reduced in size by
extrusion through an 800 nm polycarbonate filter at 50°C using the Avanti Mini Extruder.

Figure 1. Schematic of the formation and refolding of DPPC sheets to form eLiposomes. The brown circles
on the left represent small DPPC vesicles. These vesicles were unfolded into sheets with the addition of
ethanol. Excess ethanol was removed by centrifugation and emulsion droplets (represented by small red
circles) were added to the sheets. Sheets were refolded into closed vesicles with the addition of heat, and
neighboring emulsion droplets were encapsulated inside.

Empty eLiposomes, or liposomes refolded from interdigitated sheets without emulsion
present, were prepared as a negative control. The same method used to form the eLiposomes
was employed, but emulsion was replaced with an NaCl solution, creating empty lipid vesicles as
an analogous negative control.
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4.2.5 Calcein encapsulation and separation
Calcein-containing samples were prepared for quantification of leakiness and ultrasoundinduced release. During vesicle formation, calcein was encapsulated inside of the eLiposomes at
a concentration of approximately 15 mM by adding a 30 mM calcein solution to the solution of
sheets and emulsion droplets. At this concentration, the calcein was self-quenched. The external
calcein concentration was reduced by allowing the sample to settle at the bottom of the
microcentrifuge tube for a few hours. Due to their relatively high density, the vesicles settled to
the bottom of the tube in a thick gel-like phase. The top vesicle-free layer was removed and the
samples were resuspended in a NaCl solution with the osmolarity matched to the calcein solution
inside of the eLiposomes.

This created samples with concentrated calcein inside of the

eLiposomes and dilute calcein on the outside. Osmolarity of calcein solutions was measured
using a vapor pressure osmometer (Wescor Vapro 5520) in order to match this osmolarity with
NaCl.
For some experiments, conventional liposomes were prepared by thin film hydration
followed by extrusion through a filter with the desired pore size. Due to the lack of a large
density difference between conventional liposomes and water, settling was not always adequate
to remove external calcein. In these cases, external calcein was removed by centrifugation
through PD-10 spin columns (GE Healthcare Biosciences, Pittsburgh, PA). Briefly, the column
was prepped by adding 1-2 mL of buffer solution and spun for 2 minutes at 800 x g. The
liposome solution was then added to the column and it was again centrifuged at 800 x g for 1.5
minutes.
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4.2.6 Purification by sucrose cushion
Some samples were further purified by centrifugation on a “sucrose cushion” to remove
unencapsulated emulsions and additional external calcein from the eLiposomes. Sucrose and
NaCl solutions were prepared to match the internal osmolarity of the eLiposomes. The mixture
of eLiposomes containing unencapsulated emulsion droplets was added to the bottom of a 1.5
mL microfuge tube.

Approximately 0.4 mL of the NaCl solution was added to the

microcentrifuge tube. Then, using a glass Pasteur pipette, approximately 0.4 mL the sucrose
solution was gently pipetted to the bottom of the microcentrifuge tube, underneath the NaCl
layer. As the sucrose layer was added, the salt layer was forced up, creating two distinct phases
of different densities. The sucrose had a density of 1.12 g/cm3 and the NaCl solution had a
density of 1.02 g/cm3. The sample was centrifuged for 10 min at 3000 rpm (504 g) using a fixed
rotor centrifuge (Eppendorf 5415 C, Hauppauge, NY). Upon centrifugation, free emulsion
droplets collected at the bottom of the sucrose layer due to their relatively high density (1.67 g/
cm3 for PFC6 and 1.63 g/ cm3 for PFC5).

The eLiposomes, with an average density of

approximately 1.05 g/ cm3, would gather at the interphase between the sucrose and salt layers.
This interphase layer was then carefully removed from the top to bottom with a pipette.
This sucrose cushion technique was also used to verify the presence of emulsion droplets
in various samples. The emulsion samples were added to the NaCl phase. The tube was then
centrifuged and examined to determine if a pellet had collected at the bottom of the sucrose
phase, indicating the presence of emulsion droplets.
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4.2.7 TEM microscopy
Some samples were imaged by cryogenic transmission electron microscopy (cryoTEM).
A few μL of solution were placed on a holey-carbon-coated copper grid. The grid was then
blotted with filter paper and plunge frozen in liquid ethane with an FEI Vitrobot (Hillsboro,
Oregon, USA). Frozen grids were stored in liquid nitrogen until transferred to a Gatan 626
cryoholder (Pleasanton, California, USA), which maintained the samples at approximately
−180°C during imaging. CryoTEM images were recorded at 300kV on an FEI Tecnai F30
transmission electron microscope. To improve contrast, the objective lens was under-focused by
several micrometers and images were recorded on a Gatan 1024 × 1024 CCD camera.
Some samples were also imaged by TEM using negative staining. The sample was
placed on a continuous carbon-coated copper grid and allowed to settle for 20 seconds before
being blotted away by filter paper. After rinsing the grid by placing it on a large drop of water
for 2-3 seconds, a uranyl acetate solution was added to the grid for 20 seconds before the
solution was blotted away and the grid was allowed to dry. Negative staining images were
recorded at 120 kV on an FEI Tecnai 12 transmission electron microscope with a Gatan 1024 x
1024 CCD camera.

4.2.8 Calcein release
A correlation of calcein fluorescence versus concentration was prepared for the
QuantaMaster fluorometer by varying the concentration of calcein (see Figure 2).

At

concentrations below 8 µM calcein, the plot of fluorescence intensity versus calcein
concentration is linear.

At concentrations above 500 µM the fluorescence of calcein is

essentially completely self-quenched.
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Samples of eLiposomes were prepared in order to take advantage of the two extremes of
this fluorescence curve. eLiposome samples containing self-quenched (15 mM) calcein were
diluted by adding 20 µL of sample to a disposable UV/VIS-range cuvette with a 10 mm path
length (Fisher Scientific cat# 14-995-130). Two (2) mL of NaCl solution were added to the
cuvette to achieve a target external calcein concentration of 1 to 5 µM in order to operate in the
linear region of the concentration curve for calcein.

The resulting eLiposomes had very

concentrated encapsulated calcein that would not contribute to the overall solution fluorescence
until released and an external solution with fluorescence in the linear range for calcein.
Standards were prepared at 1 µM and 5 µM to test the fluorescence emission (counts/second)
expected for the target concentration range in order to verify that experiments were being run
within these concentrations.

Figure 2. Plot of fluorescence versus calcein concentration in the fluorometer. The insert shows the low end
of the plot; below approximately 8 µM fluorescence and calcein concentrations demonstrate a linear
relationship. At concentrations above approximately 500 µM, fluorescence is essentially completely selfquenched.
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For release experiments, baseline fluorescence data was collected for 10 seconds at 4 data
points per second. The cuvette was then removed from the fluorometer and ultrasound was
applied to the sample. As concentrated (self-quenched) calcein was released from the interior of
the eLiposomes into the surrounding solution, it was diluted below its self-quenching
concentration. Fluorescence was again measured after sonication. Finally 25 µL of 5% Triton
X-100 was added to lyse any remaining liposomes and a final fluorescence was measured.
Because experiments were performed at concentrations within the linear range of the
fluorescence versus concentration plot, percent release of calcein could be determined using the
following equation:

% 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 =

𝑓𝑈𝑆 −𝑓𝑖

𝑓𝑓𝑢𝑙𝑙 −𝑓𝑖

∙ 100%

(2)

where fi is initial fluorescence, fUS is the fluorescent signal after sonication, and ffull is the
fluorescence after complete calcein release using Triton X-100. Each value was determined by
averaging 30 fluorescence data points. Release experiments were performed on eLiposome
samples and empty control liposome samples. Experiments were also performed on empty
control samples mixed with emulsion droplets after the formation of the control vesicles, such
that the emulsion droplets were external to the liposomes instead of internal.
For exposure to 20-kHz ultrasound, a 3-mm transducer was inserted directly into the
cuvette. For exposure to 525-kHz ultrasound the sample was transferred to the bulb of a 3-mL
transfer pipet. The pipet bulb was then positioned in a water bath at the transducer’s focal point.
After ultrasound exposure, the sample was transferred back to the cuvette to record fluorescence
after ultrasound and after the addition of Triton X-100.
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4.2.9 Incorporation of folate into eLiposomes and emulsions
Folate was attached to DSPE-PEG2000-amine using techniques that had previously been
established [121]. Briefly, folic acid was dissolved in dimethyl sulfoxide (DMSO). DSPEPEG2000-amine and N,N'-dicyclohexylcarbodiimide (DCC) in pyridine were added to the
solution. The reaction flask was shielded from light and the reaction was allowed to proceed
under nitrogen. After 4 hours, the pyridine was removed by evaporation and water was added.
Unreacted folic acid, byproducts, DCC, and DMSO were removed using a 3500 molecular
weight cut-off dialysis bag. A drop of hydrochloric acid was added to the aqueous phase to
protonate the product to make it more soluble in chloroform. The DSPE-PEG2000-folate was
then extracted by adding an equal volume of chloroform. During this extraction, the folate
shifted from the aqueous phase to the chloroform phase, as observed by the chloroform
becoming yellow in color. Chloroform was evaporated to isolate the folate-conjugated lipid.
Attachment of the folic acid to DSPE-PEG2000-amine was confirmed by NMR [122].
Micelles were prepared by dissolving 2 to 6 mg of DSPE-PEG2000-folate in 0.6 mL of
DMSO, followed by the addition of 5.4 mL of water. The resulting solution was dialyzed
against water using a 3500 molecular weight cut off dialysis bag to remove the DMSO. The
original dialysate was replaced after 4 hours; then dialysis was continued overnight.
Folate was added to eLiposomes to a concentration of approximately 1.2 mol% by adding
DSPE-PEG2000-folate micelles to a previously prepared sample of eLiposomes in a 1.5 mL
Eppendorf tube. The micelles were allowed to incubate with the eLiposomes for at least 1 hour
to allow lipid interaction and transfer [10, 122, 123].

For in vitro experiments with only

emulsion, folate was added to the surface of emulsion droplets by mixing DSPE-PEG2000-folate
with the DPPC prior to emulsion formation by sonication.

45

4.2.10 Cell culturing and ultrasound exposure
HeLa (CCL-2™) cells were grown in DMEM (Sigma Aldrich) media supplemented with
10% fetal bovine serum (FBS). Trypsin was used to passage and split the cells; the cells used in
experiments were passaged less than 20 times. Cells were grown in 12-well plates and media
was changed to folate-free media 48 hours prior to the addition of eLiposomes or emulsions.
200 µL of eLiposome sample or emulsion was added to each well and allowed to incubate for 2
hours before application of ultrasound. Prior to ultrasound exposure the cells were washed two
times with PBS. Ultrasound was applied to the cells by adding 3 mL of media to the wells and
inserting the 3-mm diameter 20-kHz ultrasonic probe directly into the culture wells with the tip
approximately 2 cm above the cell monolayer. Ultrasound was applied at 1 W/cm2 for 2
seconds. After sonication, the media was removed from all of the wells. 200 mL of fresh media
or PBS was added to the wells and cells were removed from the surface with a cell scraper.
Cells were stored on ice until viewed with the confocal microscope. Fluorescence intensity in
the cells was measured using ImageJ software.
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5

PERFLUOROCARBON EMULSIONS

5.1 Theory
Emulsions are formed when two immiscible liquids are combined in a single container
and agitated such that a dispersed phase of small droplets is suspended within the continuous
phase. Because the two phases are inherently immiscible, the resulting emulsion can be unstable
and susceptible to the phases re-separating.

Emulsions can also be susceptible to droplet

coalescence. In order to overcome the challenges of emulsion instability, emulsion droplets are
typically stabilized with surfactants. In general, more surfactant added to the solution can lead to
the stabilization of smaller droplets, up to a certain limit. This limit is controlled by the ability of
the surfactant to pack into a highly curved surface.
This study investigates emulsions of perfluorocarbon in water. Perfluorocarbons offer
the intriguing possibility of ultrasound-induced phase change from liquid to vapor due to the
relatively high vapor pressures of these liquids (see Table 1). As mentioned in Chapter 2.1,
ultrasound is defined as cyclic pressure waves. During the low-pressure phase of an ultrasound
wave the local pressure can drop below the vapor pressure of the liquid emulsions, creating a
thermodynamic potential to vaporize and form bubbles.
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Table 1. Normal Boiling points and Vapor Pressures of various perfluorocarbons.
Values were obtained from the DIPPR database.

Perfluoropropane (PFC3)
Perfluorobutane (PFC4)
Perfluoropentane (PFC5)
Perfluorohexane (PFC6)
Perfluoroheptane (PFC7)

Normal
Boiling point
-37°C
-1°C
29°C
57°C
82°C

Vapor Pressure Vapor Pressure
at 24°C
at 37°C
862 kPa
1,213 kPa
261 kPa
387 kPa
84 kPa
135 kPa
28 kPa
48 kPa
10 kPa
18 kPa

For several PFCs, the difference in vapor pressure and atmospheric pressure that must be
overcome to induce vaporization is small enough to be achieved at reasonable ultrasound
intensities, making them potential candidates for this strategy. The ideal choice should be liquid
at temperatures of interest, but have vapor pressures that are relatively close to atmospheric
pressure.

For example, perfluoropentane has a relatively high vapor pressure at room

temperature, and perfluorohexane has a high vapor pressure at biological temperatures, making
these two liquids interesting for drug delivery applications. Nano-sized vaporizing emulsion
droplets could penetrate deep into tissues due to their small size and then be induced to form
bubbles for cavitation. This would retain the advantages of microbubbles (ultrasonic cavitation)
while overcoming some of their shortfalls (large size). The cavitating bubbles could increase
cell permeability and/or activate drug release from the emulsion droplets or from other carriers
such as liposomes or micelles.
Besides vapor pressures and boiling points, another interesting factor that affects
ultrasound-induce vaporization of emulsions is the Laplace pressure imposed at a curved phase
boundary. Laplace pressure is the pressure difference between the inside and the outside of a
bubble or droplet caused by surface tension at the interphase and the curvature of the interface.
For a spherical interface, the Laplace pressure is defined as
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𝑃𝐿𝑎𝑝𝑙𝑎𝑐𝑒 =

2∙𝛾

(3)

𝑟

where γ is the interfacial energy of the droplet/water interface and r is the radius of the droplet.
The pressure on the interior of an emulsion nanodroplet is therefore the sum of the
environmental pressure and the Laplace pressure, or:

𝑃𝑖𝑛𝑠𝑖𝑑𝑒 = 𝑃∞ +

2∙𝛾
𝑟

(4)

where Pinside is the pressure inside of the droplet, P∞ is the local pressure of the continuous water
phase. The difference between this pressure inside of the droplet and the liquid vapor pressure of
the emulsion droplets is the reduction in local pressure that must be imposed by ultrasound in
order to provide a driving force for vaporization.
Therefore, there are two competing effects when considering emulsion droplets for
ultrasound-induced drug delivery. Small droplets are desired in order to allow extravasation into
tissues. However, as the size of the emulsion droplet decreases, the Laplace pressure increases
and the amplitude of ultrasound required to vaporize the droplet increases substantially.
Equation 2 helps elucidate the importance of the surfactant used to stabilize an emulsion.
The surfactant stabilizes the droplets and reduces the interfacial energy, γ; therefore, surfactants
that are efficient at reducing interfacial energy will result in less additional pressure on the
droplet. This, in turn, translates to the ability to vaporize the droplet at relatively mild ultrasound
intensity. The Laplace pressure across the interface of the nanoemulsions can be estimated by
using the interfacial tension reported for other perfluorocarbon emulsions stabilized with
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phosphocholines [124]. Interfacial tension for a PFC droplet in water stabilized with DPPC can
be estimated to be about 4 mN/m.
The Laplace pressure imposed on emulsion droplet is intriguing for another reason. The
additional pressure imposed on emulsion droplets effectively raises the boiling point of small
droplets above their normal boiling point, allowing them to remain in the liquid phase well above
biological temperatures [53, 56].

The Antoine equation can be used to predict and plot

temperatures at which droplets will boil as the diameter decreases [56, 60].

Figure 3

demonstrates the estimated boiling point of emulsion droplets for several perfluorocarbons as a
function of droplet diameter. Antoine equation constants for perfluorocarbons were obtained

Effective Droplet Boiling Point°C

from the National Institute of Standards and Technology database [125].
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Figure 3. Predicted boiling points for emulsions formed from perfluorobutane (PFC4), perfluoropentane
(PFC5), and perfluorohexane (PFC6) as a function of diameter using the Antoine Equation. Body
Temperature (37°C) is also included as a point of reference.
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Although the normal boiling point for PFC5 is less than body temperature, the effective
boiling point of droplets exceeds the 37°C for droplets smaller than about 500 nm in diameter
due to the Laplace pressure across the interphase. Therefore, if emulsion droplets can be formed
from PFC5 at small sizes (for example, at low temperatures), the resulting emulsion droplets will
be below their effective boiling point, even if heated to 37°C. This technique could create
metastable PFC5 emulsion droplets until disrupted by ultrasound. With surfactants that result in
a higher interfacial energy, it may possible to employ perfluorocarbons with an even lower
boiling point such as PFC4 [56].

Figure 4. Two possible scenarios of ultrasound induced phase change. Droplets may vaporize during the
negative phase of ultrasound, but re-condense after the ultrasound has been removed (A). This situation is
likely with perfluorocarbons with high boiling points. It is also possible that perfluorocarbon emulsions could
vaporize and then remain as microbubbles, even after the ultrasound field has been removed (B). This
scenario is likely in the case of metastable droplet formed from liquids with low boiling points.

The ability to form metastable emulsion droplets allows the conceptualization of two
scenarios for droplet vaporization (see Figure 4). For perfluorocarbon liquids that have boiling
points that are higher than the temperature of the continuous phase (for example, PFC6 at 37°C
or PFC5 at 24°C), droplet vaporization will be reversible, and the perfluorocarbon bubble may
be able to condense back into a liquid droplet when the ultrasound is removed (Figure 4A).
However, perfluorocarbon liquids that have a boiling point that is lower than the temperature of
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the continuous phase (such as PFC5 droplets at 37°C) may form metastable droplets, and
vaporization will be irreversible as the Laplace pressure holding the droplet in the liquid phase
has been reduced (Figure 4B).

This irreversible phase change would create a persistent

oscillating bubble. These two scenarios each have advantages and disadvantages. In the case of
reversible vaporization, the droplets could re-condense after ultrasound exposure, which may
allow them to be more readily cleared from the physiological system and avoid potential
embolism.

Irreversible vaporization, however, will have lower ultrasound thresholds for

vaporization, and the resulting bubbles may provide more efficient cavitation nuclei.
Lastly, it is likely that the ability of a vapor phase to nucleate may play a significant role
in the ultrasound-induced phase change of emulsion droplets. Even when the rarefactional phase
of ultrasound may overcomes the Laplace and vapor pressure of the droplet and provides a
thermodynamic potential to vaporize, this process may not be instantaneous. The rate at which
the vapor phase can form may limit the potential of a short ultrasound phase to vaporize the
droplets.

5.2 Emulsion droplet formation
5.2.1 Shaking versus ultrasound
DPPC, Zonyl (a commercially available fluorosurfactant), and perfluorooctanoic acid
(PFOA) were explored as surfactant options for stabilizing emulsion droplets. PFC6 was used in
preliminary experiments to compare the ability and efficiency of these surfactants when forming
emulsions. Emulsions were formed by sonication with a 20-kHz ultrasound probe and with
mechanical shaking using a high speed mixer. Concentrations of approximately 10 mM of each
surfactant were used in these comparisons. All three candidates demonstrated the ability to
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stabilize droplets. PFOA and DPPC demonstrated the ability to stabilize emulsions formed by
mechanical shaking. The median diameter of these emulsions was typically between 250 and
400 nm. Zonyl, however, was not able to sufficiently stabilize droplets formed by shaking; the
mixture in the vial initially went cloudy and white, indicating mixing of phases and droplet
formation during shaking, but the water and perfluorocarbon phases separated within minutes
after shaking had stopped.

Median Diameter (nm)

600
500
400
300
200
100
0
PFOA

DPPC
Surfactant (10mM)

Zonyl

Figure 5. Median diameters of emulsion samples when prepared with ultrasound. Samples were chilled on
an ice bath and exposed to 20 kHz ultrasound for 4 minutes at 1 W/cm2. Error bars represent ± 1 standard
deviation (n=10).

Ultrasound was also explored as a method for forming emulsions. As with shaking,
emulsions were prepared with a concentration of approximately 10 mM of surfactant. Water,
PFC, and surfactant were added to a cuvette and the solution was cooled on an ice bath for
several minutes to avoid vaporization of the PFC phase during sonication. The chilled solution
was sonicated on an ice bath for 4 minutes at 1 W/cm2 via a 20-kHz probe inserted directly into
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the cuvette. Each surfactant was tested 10 times at these conditions. Zonyl, PFOA, and DPPC
all demonstrated the ability to stabilize PFC6 emulsions. However, there was a large amount of
variation in median emulsion size from one sample to the next despite being prepared in the
same way. Typical median diameters of the resulting solutions were between 250-450 nm with
Zonyl and PFOA and were between 150-400 nm with DPPC (see Figure 5). While it was
promising that various surfactants were able to form stable emulsions, these median sizes were
larger than desired. Furthermore, the wide distribution of sizes would make it difficult to
produce emulsion samples that would be consistent and repeatable enough for use as drug
delivery vehicles.
The ability to stabilize more concentrated emulsions was tested for both the shaking and
ultrasound methods. As the amount of perfluorocarbon was increased from 0.1 g per 1.5 mL of
water to 0.2 g per 1.5 mL of water, shaking became less efficient in forming the emulsions. With
the higher amounts of PFC6, emulsions were not adequately formed and stabilized by shaking
and the water and PFC phases separated shortly after shaking. Ultrasound was still able to form
stable emulsions even with the increased concentration of PFC6. For the remainder of the
project, ultrasound was chosen as the technique for forming emulsions due to its increased
versatility compared to shaking as well as being quicker and more user-friendly.

5.2.2 Comparison of surfactants
To further test the potential of each surfactant, preliminary compatibility experiments
were performed.

Each surfactant was added to conventional liposomes with encapsulated

calcein and liposomal stability was monitored with fluorescence.

When combined with

liposomes it was found that PFOA had a negative effect on the bilayer lipid membrane; when
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dilute PFOA was added to liposomes containing calcein, the stability of the membrane decreased
and calcein was released into the surrounding solution. This increased leakiness to calcein was
not observed in control liposomes or when Zonyl or DPPC was added to the liposomes. PFOA
also reacted with calcein in these preliminary compatibility experiments to form a yellow
precipitate. The resulting precipitate had an altered fluorescent spectra compared to calcein.
Because of these effects and potential toxicity associated with PFOA it was eliminated as a
candidate for stabilizing the emulsions.
The effect of Zonyl or DPPC concentration was investigated by forming emulsions with
varying concentrations of surfactant.

All other parameters, such as amount of PFC and

preparation conditions, were maintained the same. Both Zonyl and DPPC demonstrated the
ability to stabilize smaller droplets as the amount of surfactant increased. Initially, as the
concentration of DPPC was increased, the median diameter decreased quickly (see Figure 6A).
At approximately 5 mM DPPC, the average diameter approached 200 nm.

At this PFC

concentration, additional DPPC did not have a significant contribution in stabilizing smaller
droplets.

Zonyl-stabilized emulsions also approached 200-nm diameters, but only at much

higher concentrations (see Figure 6B). At comparably low (5-10mM) concentrations, Zonyl was
able to stabilize droplets, but average sizes were between 400 and 600 nm. Approximately 150
mM Zonyl was required in order to form 200-nm emulsions. In contrast, Zonyl did tend to form
emulsions with narrower size distributions. DPPC was chosen to stabilize emulsion droplets
throughout the rest of this study due to the much smaller amount of surfactant required to
stabilize 200-nm emulsion droplets and its well-known biocompatibility. This choice had the
added advantage of stabilizing emulsions with the same material that would be used to form
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eLiposomes later on, thus reducing the threat to destabilize the bilayer membrane with foreign
surfactants.

Figure 6. Emulsion diameters as measured by DLS as amount of surfactant (DPPC or Zonyl) was varied.
DPPC-stabilized emulsions approached 200 nm at low concentrations. While Zonyl-stabilized emulsions
approached similar median diameters, much higher concentrations were required to do so. Error bars
represent ± 1 standard deviation (n=10).

5.2.3 Effect of liquid, surfactant concentration and ultrasound exposure
After choosing DPPC as the surfactant of choice for remaining studies, the ability to
stabilize PFC5 emulsions was also examined. Similar to PFC6, ultrasound proved an effective
method for forming PFC5 emulsions stabilized with DPPC. All emulsions were formed on an
ice bath to reduce loss of PFC through vaporization and ultrasound induced heating. While this
step had been largely a precaution when working with PFC6 emulsions, the cooling was
mandatory when working with PFC5. It was initially discovered that PFC6 solutions emulsions
could be formed without cooling. Nevertheless, cooling was introduced to avoid the possibility
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of PFC6 loss. Furthermore, without cooling the diameters of the resulting emulsions tended to
be less consistent, especially at longer sonication times. In contrast, when PFC5 solutions were
sonicated without an ice bath a large amount of foam would form as the PFC5 was vaporized.
This foam would sometimes overtake the entire sample, rendering the emulsion unusable. When
the solution was cooled on an ice bath the layer of foam was either very small or completely
absent. The persistence of emulsion droplets was verified by adding the emulsion to the top
phase a “sucrose cushion” and centrifuging (see Chapter 4.2.6). The 1M sucrose layer had a
density much greater than perfluorocarbon bubbles, slightly greater than an aqueous suspension
of liposomes, but less dense than liquid perfluorocarbons. The collection of a pellet at the
bottom of the sucrose layer verified the preservation of emulsion droplets.

Figure 7. Median diameters of PFC6 and PFC5 emulsions at DPPC concentrations ranging from 0.1 to 10
mM. The diameter seems to level of at approximately 200 nm for both PFC5 and PFC6 emulsions. Time of
ultrasound exposure was also varied. Samples were exposed to ultrasound for 1 (), 4 () and 10 ()
minutes of ultrasound. The median diameter decreases as ultrasound exposure time increases. However,
sizes still level off at approximately 200 nm even as time is increased. Each data point represents the average
of 3 measurements (error bars are removed for clarity).

The effect of varying DPPC concentration was examined for both PFC5 and PFC6 by
preparing samples with a constant amount (0.1 g) of PFC and varying amounts of DPPC. The
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average diameters for both PFC6 and PFC5 emulsions decreased as DPPC concentration was
increased up to about 5 mM DPPC (see Figure 7). This lipid concentration corresponds to
enough lipid molecules to coat approximately 80% of the surface area of 100-nm emulsion
droplets. Additional DPPC would most likely form separate liposomes or additional lipid layers
on the emulsion droplet.
At low DPPC concentrations, PFC5 formed emulsions with smaller diameters than PFC6
(See Figure 7B). Once again, however, the size of emulsions formed from both PFC6 and PFC5
both leveled off at approximately 200 nm as DPPC concentration increased. The time of
ultrasound exposure also had a significant effect on emulsion diameter, with samples exposed to
ultrasound for longer times typically having small diameters. Some samples were exposed to up
to 20 minutes of ultrasound. The diameters of these emulsions, however, still seemed to level off
at slightly below 200 nm. In most cases, the presence of sufficient lipid to stabilize small
emulsions seemed to have more of an impact on final diameter.
For some experiments emulsion samples with large droplets were required in order to test
the effect of size on droplet vaporization. The target diameter for these samples was typically
450 nm. A variety of parameters were explored to form these larger emulsions. Intensities of 1
W/cm2 or higher tended to form emulsions smaller than 400 nm even at short times (10, 20 and
30 seconds). The sizes produced in these samples were sporadic, ranging from 150 to almost
500 nm. More repeatable success in forming large droplets was obtained by sonicating emulsion
samples at 0.5 W/cm2. When sonicating for short times (30 seconds and less), the PFC phase
was not always fully suspended. Furthermore, there was again a fairly wide range of average
sizes obtained. Long times (4 minutes or more) also often resulted in diameters of less than 400
nm even at low ultrasound intensities. The most consistent results were obtained by sonicating

58

for 1 minute at 0.5 W/cm2. While these parameters yielded the most consistent results, there was
still a large amount of variability. Because of this variability, samples were measured after
formation and were eliminated or reprocessed if the median size was not in between 400-500 nm.

5.3 Emulsion extrusion
5.3.1 Emulsion sizing via extrusion
While sonication had proven able to suspend the perfluorocarbon phase and form a
DPPC-stabilized emulsion, the average droplet diameter of sonicated emulsion samples varied
from 150 to 400 nm and results were not easily reproduced. Also, the size distribution generated
by sonication was often multimodal and sometimes very broad. A typical size distribution of a
PFC6 emulsion generated by sonication is demonstrated in Figure 8A.

Figure 8. Typical size distributions for PFC6 emulsion samples after formation by ultrasound (A) and after
extrusion through a 100-nm filter (B) or a 50-nm filter (C).

To better control the size of emulsion droplets, they were extruded through polycarbonate
filters having specific pore sizes.

After nanodroplets had been formed by ultrasound as

described above, they were extruded 15 times through a 100-nm or 50-nm filter at 50°C to
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control and reduce their size. These filter sizes were chosen in order to create emulsion droplets
that could be readily encapsulated inside of sub-micron liposomes.

Figure 8B and C show

typical size distributions of PFC6 emulsions extruded with 100-nm and 50-nm filters,
respectively. Extrusion demonstrated the ability to control the diameter of the PFC6 emulsion
droplets to approximately the size of the filter pores. Additionally, size distributions after
extrusion were much more monomodal than before extrusion.
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Figure 9. Average diameter of emulsions after formation by sonication at 1 W/cm2 for 4 minutes or after
extrusion through a 50 or 100 nm filter. The size of both PFC5 and PFC6 emulsions were controlled by
extrusion. Not only did extrusion control the diameter to close to the filter size, but the variability from
sample to sample was greatly reduced. Data is reported as the average of sample medians ± 1 standard
deviation (n=10).
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In order to test repeatability and efficiency of extruding, emulsions were formed and
sized with DLS at least 10 times for each of the filter sizes and each PFC liquid (Figure 9). The
median diameter of PFC6 samples extruded through a 100-nm filter was 104 nm with a standard
deviation of 13 nm. PFC5 emulsions extruded at 100 nm had an average size of 107 with a
standard deviation of 17. Similarly, when extruded through a 50-nm filter, the average diameter
of the PFC6 droplets was 52±11 nm and the average diameter of PFC5 droplets was 61±21 nm.
In contrast, non-extruded PFC6 emulsions had an average diameter of 220±99 nm and nonextruded PFC5 emulsions had an average diameter of 233±101 nm. Not only was the size of the
emulsion controlled, but the variability from sample to sample was also greatly reduced in both
PFC5 and PFC6

5.3.2 Effect of temperature
In order to effectively control droplet size, the extrusion step had to be performed above
the transition temperature of DPPC (Tm = 41°C). Attempts to extrude at room temperature gave
mixed results. Usually the filter would become clogged and eventually rupture, especially with
PFC6 emulsions. When the filter did not break, PFC6 emulsion droplets would often stay the
same size or sometimes even increase in diameter. PFC5 emulsions would sometimes decrease
in size and would sometimes stay approximately the same size as before being extruded. Similar
to PFC6 emulsions, PFC5 emulsions were very difficult to extrude at room temperature and the
extrusion process would often break the filter. These problems were eliminated when the
extrusion step was performed at 50°C; excessive amounts of force were no longer required to
pass the solution though the filter and the measured sizes were typically closer to the membrane
pore size. This can be attributed to stiff lipid membranes existing below the lipid transition
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temperature, which is 41°C for DPPC. Droplets with a stiff DPPC layer would likely get caught
in the holes of the filter. It is possible that with sufficient pressure the shape of the droplet
elongated in order to pass through the pore, only to re-assume a spherical shape on the other side.
This would explain the ability of droplets to stay the same size throughout extrusion as well as
the higher force requirement for extrusion and the tendency to rip filters. Heating above the
transition temperature of the lipid would have caused the droplet’s membrane to become more
shapable and fluid, allowing it to more readily elongate and form new, smaller droplets while
being forced through the filter.
Despite being processed above the boiling point for PFC5, emulsion droplets persisted
and their size was controlled. The ability to process PFC5 emulsions above the normal boiling
point of PFC5 is most likely due to the high Laplace pressure imposed on the droplets at submicron sizes, additional pressure imposed in the syringes of the extruder, or some combination
thereof. PFC5 emulsions would occasionally vaporize and foam when being processed or when
being removed from the syringes. This problem was remedied by removing the Avanti Mini
Extruder apparatus from the heating block and allowing the syringes to cool before removing the
syringe from the extruder and emptying the emulsion. The presence of emulsion droplets after
heating and extrusion was once again verified using a sucrose cushion. After centrifugation, a
pellet had collected at the bottom of the dense sucrose phase indicating the liquid
perfluorocarbon droplets were still present. Persistence of nano-sized emulsion droplets was
further confirmed by TEM.
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5.4 CryoTEM imaging of emulsion droplets
Emulsion droplets were imaged using cryoTEM. This technique allows structures to be
frozen and viewed in their natural state. Images confirmed the average sizes observed by DLS,
and better demonstrated the width of the distribution, with droplets varying from 30 to 200 nm.
An unexpected wide variety of appearances was observed in the emulsion droplets. Figure 10
shows two cryoTEM images of an emulsion that was extruded through a 100 nm filter. The
droplets in this particular sample have a median size of 88 nm. The two views presented in
Figure 10 represent typical variability within a single sample observed during one microscope
session. The dark structure with a distinct edge in the top left of the first panel is the holey
carbon copper grid used to support the frozen sample.

Figure 10. Two cryoTEM images of PFC6 emulsions extruded through a 100-nm filter. This emulsion
sample had individual diameters ranging from 45- 140 nm and a median droplet diameter of 88 nm. The
droplets demonstrated several distinct appearances. The dark structure with a distinct edge in the top left of
the left panel is the holey carbon copper grid used to support the frozen sample.
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The imaged droplets had three distinct appearances: 1) dark electron dense spots, 2) very
light spots (brighter than the vitreous ice background), or 3) a combination of 1 and 2, with a
dark circle surrounding a lighter one. Droplets were counted from six TEM images; 40% of the
droplets appeared dark, 33% appeared light, and 27% appeared as a dark circle surrounding a
smaller light one. A light circle surrounding a smaller dark one was never observed. When both
shades were present in combination, the light spot stayed within the boundary of the dark area
when the stage was rotated throughout 90°, suggesting that the lighter region was contained
within the darker droplet boundary.
We speculate that these 3 distinct appearances may be due to one or more of the
following possibilities. 1) Due to the low melting temperature of PFC6, the emulsion droplets
may freeze slower or later than the water surrounding it. Hence, the frozen PFC6 may take on
two possible formations: A crystalline phase and an amorphous phase. Differences in electron
density/transparency in these phases would account for the two different droplet appearances. In
some instances, one phase could be embedded within the other, causing both shades to be present
simultaneously. However, upon closer examination, the emulsion droplets did not show any
appearance of crystallinity in either in the real-space images or after Fourier analysis (data not
shown).

2) During cryoTEM, radiation damage is commonly observed.

Sometimes, this

radiation damage may be observed spreading throughout a sample with time, especially as the
electron beam is focused on a specific area of the sample at higher magnifications.

The

perfluorocarbon liquid could act as a nucleation site for this type of damage, causing some
droplets to take on a white appearance. 3) The lighter regions could be areas of low fluorocarbon
density, such as small bubbles of vapor or air. Frozen droplets could melt or sublime with
exposure to the electron beam. This commonly happens to the ice during cryoTEM. With a
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melting temperature of -90°C, the PFC6 would melt or sublime at a lower temperature than the
ice, leaving a liquid phase or an empty hole where the frozen droplet had been. A void could
also have been created during freezing, or some of the perfluorocarbon could have been in its
vapor phase when the sample was frozen. The resulting area of low perfluorocarbon density
would most likely appear as a bright area in the images. To further examine this possibility,
emulsions were formed from perfluoropentane (PFC5) and perfluoroheptane (PFC7) following
the same procedure outlined in Materials and Methods (Chapter 4). PFC5 has a boiling point of
29°C and PFC7 has a boiling point of 82°C. As the boiling point increases, the amount of liquid
or vapor present in the sample and rate at which droplets would vaporize or sublime should
decrease. Droplets were counted from 5 or more cryoTEM views. The percent of droplets that
have the different appearances in the TEM images is reported in Table 2.

Table 2. The percentage of emulsion droplets that appear light, dark,
or dark surrounding a light circle (combination).
a

PFC5
PFC6b
PFC7c

Boiling point
29°C
57°C
82°C

Light
51%
33%
25%

Dark
40%
40%
43%

Combination
8%
27%
32%

(a) n = 84
(b) n = 315
(c) n = 68

The percentage of droplets that appear lighter than the background decreases as the
boiling point increases. The percentage of dark droplets with light spots inside of them increases
as the boiling point increases. This trend is consistent with the hypothesis that the light regions
are areas of lower perfluorocarbon density, such as small gas or vapor bubbles or liquid. The
percentage of dark droplets stays relatively constant.
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5.5 Verification of acoustic droplet vaporization
5.5.1 Microscope evidence of vaporization
In order to verify that ultrasound induced vaporization of emulsion droplets, PFC5
emulsions were placed on a microscope slide, and were covered with a thin glass coverslip. The
coverslip was viewed initially and after 5 seconds of exposure to 1 W/cm2 ultrasound. Figure 11
shows before and after images for large PFC5 droplets. Prior to ultrasound exposure only the
largest sized droplets (approximately 3-4 um) are visible (see Figure 11A). After ultrasound
exposure, many larger structures can be observed which have the appearance of gas bubbles
(Figure 11B). These newly formed bubbles vary in size up to 20 µm.

Figure 11. Large PFC5 emulsion before (A) and after (B) ultrasound exposure. Large emulsion droplets
were placed on a microscope slide and imaged prior to ultrasound exposure. 20-kHz ultrasound was then
applied for 5 seconds at 1 W/cm2 and the slide was imaged again. Before ultrasound exposure only the largest
droplets in the emulsion can be observed (A). After ultrasound exposure, droplets had vaporized and
perhaps coalesced into much larger bubbles (B). Scale bars represent 50 µm.

Overall, the resulting bubbles were larger than expected and persisted at room
temperature. For example, using the ideal gas law and liquid density, a PFC5 droplet should
expand to a 137-fold larger volume at its boiling temperature and 1 atm. The expected increase
3

in diameter would be √137, or a 5.15-fold increase in diameter. The diameter of the largest
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droplets observed in Figure 11B is approximately a 3.5 to 5 times the diameter of the largest
droplets in Figure 11A. While this is close to the expected expansion for these droplets, there are
more large bubbles in Figure 11B than expected from an emulsion with an average droplet
diameter of 450 nm. The larger size could be due to bubbles colliding and combining or due to
dissolved nitrogen and oxygen accumulating in the PFC bubble during and perhaps after
insonation. It is worth noting that laboratory manipulations and slide preparation did not result
in droplet vaporization; large droplets were not observed until after ultrasound application.

Figure 12. Small PFC5 emulsion before (A) and after (B) ultrasound exposure. 20-kHz ultrasound was
applied for 5 seconds at 1 W/cm. After ultrasound exposure, droplets had vaporized and perhaps coalesced
into much larger bubbles (B). While the appearance of the solution had changed, this change was not as
significant as observed with large PFC5 droplets. Scale bars represent 50 µm.

Figure 12 shows before and after images for small PFC5 droplets. There was again an
increase in large bubbles and structures. However, the bubbles observed after sonication were
much smaller compared to the sample with large PFC5 droplets. This indicates that either the
small droplets were less readily vaporized or that the resulting bubbles were less prone to
combine with one another into larger droplets. Two control experiments were performed: a
DPPC solution and plain water. No bubbles were observed before or after ultrasound exposure
in either of the control samples (data not shown).
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The experiment was repeated at 37°C by heating the microscope slides in an oven. Slides
were prepared and imaged prior to heating. The slides were then allowed to sit in the oven for 5
minutes to heat to 37°C and were imaged again. Finally, the slides were exposed to ultrasound
and imaged quickly to avoid cooling. Figure 13 shows results from a large PFC5 sample. It is
worth noting that there is not a significant change after heating the emulsion (Figure 13B). After
ultrasound was applied large bubbles had formed similarly to the results at room temperature
(Figure 13C).

Figure 13. Large PFC5 emulsion before heating (A) and before (B) and after (C) ultrasound exposure at
37°C. Emulsion droplets were placed on a microscope slide under a coverslip and imaged initially (A). The
slide was then heated to 37°C and imaged again prior to ultrasound exposure (B). 20-kHz ultrasound was
then applied for 5 seconds at 1 W/cm2 and the slide was imaged again (C). Heating above the normal boiling
point had no significant effect on the appearance of the emulsion (A and B). After ultrasound exposure,
droplets had vaporized and coalesced into much larger bubbles (B). Scale bars represent 50 µm.

The experiment was again repeated with small PFC5 emulsion droplets. Likewise, small
emulsion droplets did not show any significant change after being heated to 37°C (Figure 14).
Large bubbles formed after sonication. These bubbles were more numerous and more prominent
than those formed from small PFC5 emulsions at room temperature, although still not as much as
bubbles formed from large PFC5 droplets. It seems that the increase in temperature increased
the ability of the droplets to vaporize and/or to combine with one another.
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Figure 14. Small PFC5 emulsion before heating (A) and before (B) and after (C) ultrasound exposure at
37°C. The microscope slide was heated to 37°C and 20-kHz ultrasound was applied for 5 seconds at 1 W/cm2.
Heating had no significant effect on the appearance of the emulsion (A and B). After ultrasound exposure,
droplets had vaporized and coalesced into much larger bubbles (B). However, these bubbles were less
prominent than those formed from large PFC5 droplets. Scale bars represent 50 µm.

5.5.2 Acoustic evidence of vaporization
Vaporization of emulsion droplets was further verified by observing acoustic signals
generated by emulsions and control water samples. Samples were exposed to 525 kHz with 1000
cycle pulses at a 20-Hz pulse repetition frequency. The acoustic signal was detected with a
hydrophone. This signal was Fourier-transformed, creating a spectrum with peaks at frequencies
according to the oscillations of entrained bubbles. The fundamental frequency of the ultrasound
can be detected at practically any intensity. As the ultrasound intensity is increased harmonic
peaks, subharmonic peaks, and a baseline jump can be observed, typically in that order. Figure
15 demonstrates examples of these phenomena with a fundamental frequency of 525 kHz.
The fundamental peak does not provide meaningful information about the behavior of the
emulsion droplets.

The presence of higher harmonic peaks (Figure 15B) is linked to the

oscillation of these gas bubbles [30, 126]. Control samples are important because bubbles can
also form from water vapor and/or from dissolved gases that nucleate at sufficiently high
ultrasound intensities [30]. Lower thresholds in emulsion samples than in controls is likely
indicative of vaporizing perfluorocarbons that begin to oscillate and behave as gas bubbles.
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There is some debate in literature as to whether the subharmonic peak correlates to stable or
collapse cavitation [114, 115, 118, 127-129]. For our purposes, the appearance of this peak can
be considered evidence that cavitation is, at the very least, becoming more complex and chaotic
in nature. A jump in the baseline is widely accepted as being correlated to widespread collapse
cavitation; as shock waves are formed from collapsing bubbles they generate sound at all
frequencies, and result in this jump in the baseline [21, 118, 119].

Figure 15. Fourier transforms of the acoustic signal collected from emulsion samples, providing examples of
the fundamental peak (A), higher harmonic peaks (B), a subharmonic peak (C) and a baseline shift (D).

The left panel of Figure 16 compares the onset of these 3 phenomena for control samples
(water) and for large (450 nm) and small (100 nm) PFC5 and PFC6 emulsion samples when
exposed to 525 kHz ultrasound at room temperature. The initial onset of higher harmonic peaks
was much lower in emulsion samples than in control samples of water, indicating that the
emulsion droplets are indeed vaporizing when exposed to ultrasound. Interestingly, at room
temperature, there is little difference among the various emulsion samples, regardless of whether
they are formed from PFC5 or PFC6 and regardless of droplet size.
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Figure 16. Threshold values for control samples and emulsions at 525 kHz. Emulsion samples were
prepared from both PFC5 and PFC6 at 450 nm (large) and at 100 nm (small). Threshold values were
observed at 24°C (left panel) and at 37°C (right panel). Higher harmonic peaks were observed at lower
intensities in emulsion samples than in controls. At room temperature there was little to no difference in
thresholds resulting in subharmonic peaks and for the baseline jump in emulsions or control samples. There
was, however, a significant difference for intensities required to observe a subharmonic peak at 37°C. PFC5
samples also demonstrated a baseline jump at intensities lower than other samples. Data is reported as the
mean average ± 1 standard deviation (n=5).

The onset of the subharmonic peak also occurred at lower intensities for the emulsion
samples compared to controls. However, at room temperature the difference between control
and emulsion samples was much less pronounced for this phenomenon. Because this peak is
connected with more complex bubble dynamics, it may indicate the presence of more persistent
bubbles. It appears that intensities required to observe this in room temperature emulsion
samples are close to intensities required to nucleate persistent bubbles from water. This is not
surprising as the water used for control samples was exposed to similar treatment as emulsion
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samples and would therefore likely be saturated with dissolved gases. Compared to each of the
other emulsion samples, large PFC5 droplets demonstrated a statistically significant lower
intensity threshold for the emergence of the subharmonic peak. This lower intensity threshold
suggests that large PFC5 droplets form persistent bubbles that can cavitate chaotically at lower
intensities than the other emulsions. This is likely the result of PFC5 having a higher vapor
pressure than PFC6. Also, larger droplets are expected to have less Laplace pressure than small
droplets. Interestingly, at 24°C there was no difference in the onset of the baseline jump between
controls or the various emulsion droplets. It seems that this intensity is sufficient to create
bubbles and cause collapse cavitation regardless of the presence of emulsion droplets.
As the temperature was increased to 37°C, there was no difference ultrasound thresholds
observed in control samples compared to the results at 24°C (See the right panel of Figure 16).
For emulsion samples, the higher temperature is expected to result in a higher vapor pressure,
making it easier to overcome the vapor pressure with the negative phase of an ultrasound wave.
The thresholds for observing higher harmonic peaks were significantly lower at 37°C for all of
the emulsion samples except for the small PFC6 emulsion. Again, this is likely because of the
lower vapor pressure of PFC6 and the higher Laplace pressure imposed on small droplets.
Compared to room temperature samples, the subharmonic peak was observed at much lower
ultrasound intensities in emulsion samples at elevated temperature; these differences were
statistically significant for each emulsion liquid and size (Student t-test, p < 0.05). This suggests
that the increased temperature makes it easier to form bubbles, and that these bubbles can persist
more readily in order to approach a state of transient cavitation. For control samples and for
PFC6 samples, the emergence of the baseline shift was not significantly different at 37°C
compared to room temperature. However, a baseline shift was observed in PFC5 emulsion
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samples at much lower ultrasound intensities when the sample was heated to 37°C, suggesting
that in higher vapor pressure liquids the temperature can play a role in their ability to form
bubbles and to subsequently undergo collapse cavitation. It should also be noted that large PFC5
emulsions underwent this phenomenon at a lower intensity than small PFC5 emulsions, once
again supporting the hypothesis that Laplace pressure has an effect on the ability of emulsion
droplets to form bubbles and to undergo collapse cavitation.
Experiments with acoustic phenomena were repeated at 1.58 MHz (Figure 17). The
trends observed at 525 kHz were all essentially the same, but the intensities required for the
onset of each phenomenon were much higher at 1.58 MHz. For example, the higher harmonic
peaks were first observed at 67 W/cm2 for controls and at approximately 14 W/cm2 for emulsion
samples at 525 kHz.

These peaks were not observed until 216 W/cm2 in water and

approximately 90 W/cm2 in emulsion samples at 1.58 MHz. Likewise, the baseline shift was
observed in all samples at about 380 W/cm2 at 525 kHz. The baseline shift was not observed
until 3500 W/cm2 at 1.58 MHz. Increasing temperature from room temperature to 37°C also had
similar results at 1.58 MHz compared to results at 525 kHz. Most notably, the threshold for the
baseline jump remained approximately the same in control samples and in PFC6 samples but was
significantly reduced in PFC5 samples.
It should be noted that the phenomena that were observed are linked with bubble
dynamics, not necessarily droplet vaporization. While the presence of these phenomena does
indicate the presence of a gas phase and provide hints about the behavior of the emulsion
droplets, it does not necessarily provide precise threshold values of emulsion droplet
vaporization behavior. The discrepancy between controls and emulsion samples, however, does
support the hypothesis that ultrasound has the ability to vaporize emulsion droplets by
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demonstrating that ultrasound-induced droplet vaporization leads to the introduction of a gas
phase at much lower intensities when emulsion droplets are present.

Figure 17. Threshold values for control samples and emulsions at 1.58 MHz. Emulsion samples were
prepared from both PFC5 and PFC6 at 450 nm (large) and at 100 nm (small). Threshold values were
observed at 24°C (left panel) and at 37°C (right panel). Data is reported as the mean average ±1 standard
deviation (n=5).

Experiments were repeated at 500 cycles/pulse with no significant difference in results,
suggesting that 500 ultrasound cycles are capable of creating the same vaporization and
cavitation events observed at 1000 cycles. Experiments were also repeated with a continuous
wave. Counter intuitively, the thresholds for the various peaks were higher with a continuous
wave. These results suggest that acoustic decoupling may be occurring when a continuous wave
is applied. Acoustic decoupling is a phenomenon in which incoming high intensity ultrasound
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induces the formation of cavitating bubbles at the entry of the sample. The bubbles then scatter
ultrasound and prevent it from penetrating deeper into the sample. Thus it appears to the
observer that there is less cavitation occurring in the sample as the acoustic intensity increases.
There was no evidence of acoustic decoupling when short pulses were applied.

5.6 Emulsion-aided release from conventional liposomes
While emulsions have shown some promise as drug and gene carriers, they also have
several disadvantages compared to other types of drug carriers. For example, many drugs are not
very soluble in the very hydrophobic oil phase. This limits the amount of drug that can be
carried by emulsions to the amount that can be attached to the surface or carried in the surfactant
layer. Because the drug load is most likely carried on the surface of the droplets, emulsions also
have only a limited ability to sequester the drug and prevent interactions with non-target tissues.
In contrast, liposomes and micelles have a larger interior volume that can carry and sequester
their payload. Liposomes, as mentioned previously, are a particularly versatile drug carrier.
However, liposomes are not inherently responsive to ultrasound and ultrasound-mediated release
from them is largely dependent on neighboring bubbles. The size of these neighboring bubbles
limits the ability to take advantage of the EPR effect in combination with ultrasound-induced
drug targeting.
It is possible that using liposomes together with emulsion droplets may provide a method
to utilize the advantages of both particles. The liposome may add versatility, increased drug
loading and effective sequestering.

Co-administered emulsion droplets could vaporize into

bubbles and provide cavitation nuclei while retaining the ability to extravasate with the
liposomes due to their small size. DPPC liposomes containing calcein at a self-quenching
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concentration were prepared by film hydration in a 15 mM calcein solution and extruded through
a 200 nm filter. Some of the external calcein was removed on a GE PD-10 spin column. A
PFC5 emulsion was prepared with an average diameter of 200 nm. In order to investigate the
possibility of increasing ultrasound-induced drug release from liposomes with emulsion droplets,
20 µL of the liposome solution and 20 µL of the emulsion were diluted into 2 mL of PBS. The
encapsulated calcein did not add to overall fluorescence and the surrounding solution was within
the linear range of the fluorescence versus concentration curve for calcein. As calcein was
released from the liposomes and diluted into the surrounding solution, the fluorescence of the
solution increased.
Figure 18 shows the amount of calcein released from liposomes with and without the
presence of PFC5 emulsion droplets. Exposure time was varied from 2 second to 50 seconds and
experiments were performed at 0.5 W/cm2, 1 W/cm2 and 2 W/cm2. At short times there was not
a significant difference in calcein release from liposomes with or without external emulsion
droplets. As time increased, there was increased release of calcein from samples with emulsion
droplets compared to those without; this difference was significant at times longer than 30
seconds. It was unexpected that this amount of time was required to observe an increase in
calcein release from liposomes with external emulsion droplets. This could indicate that the
emulsion droplets require time to vaporize and/or to coalesce into large oscillating bubbles with
the ability to contribute to calcein release. At short times, droplet vaporization may have not
generated enough mechanical shear to affect the liposomes. At longer times, the droplets may
have coalesced into larger bubbles and/or aided in the nucleation of dissolved gasses to add to
cavitation.
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Figure 18. Calcein release from 200 nm DPPC liposomes with () and without () the presence of 200 nm
PFC5 emulsion droplets. Exposure time was varied from 2 to 50 seconds and samples were exposed to 0.5, 1
or 2 W/cm2 ultrasound at 20 kHz. Each point represents the average of 3 experiments ± 1 standard deviation.

It should be noted that while there was a significant increase in calcein release at longer
exposure times, the increase was not substantial. For example, liposomes with external emulsion
droplets released 19% of their calcein after 50 seconds of ultrasound at 2 W/cm2 and control
liposomes released 14% after this same exposure. This increase of 5%, although statistically
significant, offers little practical improvement.
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6

eLIPOSOMES

6.1 eLiposome definition and motivation
In order to better take advantage of the versatility of liposomes together with the
ultrasound sensitive nature of emulsion droplets, a novel drug carrier was developed. The
proposed drug carrier is called an eLiposome, defined as a liposome containing vaporizable
emulsion droplets. The eLiposomes would have the advantages of conventional liposomes while
adding an ultrasound responsive component. The emulsion droplets may vaporize when exposed
to ultrasound and form an oscillating gas bubble that could increase drug release from the
eLiposome.

Furthermore, the expanding vapor phase may be able to disrupt the bilayer

membrane without ongoing cavitation and/or gas nucleation. In contrast to bubbles and other
ultrasound sensitive particles, the nano-sized emulsion droplets allow the carrier to take on an
ultrasound sensitive component without sacrificing key characteristics of liposomes.
Specifically, eLiposomes must have the ability to be formed at nano-scales sizes. Also, the
versatility of liposomes that comes from the ability to tune the lipid composition should be
retained in eLiposomes. Lastly, eLiposomes must retain the ability to sequester and protect a
therapeutic payload.
During the low pressure phase of an ultrasound wave, the local pressure drops below the
high vapor pressure of the liquid emulsions, creating a thermodynamic potential to vaporize.
The expanding vapor phase stretches and disrupts the surrounding membrane and releases the
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encapsulated material because lipid bilayers can sustain only about a 3% expansion [130, 131].
Two possible representations of this are illustrated in Figure 19. As the vapor phase expands it
may stretch the membrane, creating small rips and expelling the encapsulated material (Figure
19A). This scenario is perhaps most likely with small droplets relative to eLiposome size and
with lower vapor pressure liquids; as discussed in Chapter 5, perfluorocarbons with lower vapor
pressures may be more difficult to vaporize and will collapse back to liquid droplets when no
longer exposed to the low pressure phase of an ultrasound wave. In this scenario, the gaps
formed in the stretching membrane could potentially close during each cycle of ultrasound and
following ultrasound exposure. Alternatively, if the expansion is more violent and/or if the
volume of perfluorocarbon is more substantial, the membrane could be fragmented by the
expanding vapor phase and associated cavitation events (Figure 19B).

Figure 19. Proposed mechanisms of ultrasound-induced release from eLiposomes. Small red circles
represent calcein or encapsulated drugs. In each panel the medium-sized circle inside the liposome
represents a liquid perfluorocarbon emulsion droplet. When exposed to the low pressure phase of an
ultrasound wave, the droplet vaporizes and expands, disrupting the bilayer membrane and releasing the
contents from the eLiposome. A small expansion may stretch and rip the membrane and force out some of
the payload (A), or it may more completely destroy the liposome by fragmenting the bilayer membrane (B).
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6.2 eLiposome formation via the 2-step sheet refolding method
Lipid sheets were formed by adding alcohol to a solution of DPPC SUV’s (small
unilamellar vesicles).

A DPPC lipid solution was prepared at 30 mg/mL.

Initially after

hydration, this concentrated DPPC solution was opaque and white. After SUV’s were formed by
sonication or by extrusion, the solution had a translucent bluish color (see Figure 20A and 20B).
Ethanol was added dropwise while stirring to the SUV’s to slightly above a sheet-formation
threshold value (approximately 2-3 M) [98]. As the ethanol was added, the color of the solution
transitioned from a translucent bluish hue to opaque white (Figure 20C). The viscosity of the
solution increased substantially as the SUV’s unfolded into sheets and the liquid solution
transitioned to a gel (see Figure 20D). This change in appearance and viscosity is indicative of
the formation of lipid sheets. As alcohol interacts with the bilayer membrane, the lipid heads
tend to swell. The membrane becomes thinner and stiffer as the lipids transition from a bilayer
gel phase (Lβ) to an interdigitated gel phase (LβI) [132, 133]. This stiffening reduces the ability
of the membrane to bend into small spheres, and small liposomes unfold into sheets. The
layering of continuous sheets compared to the suspension of independent spheres is responsible
for the physical changes described above. These sheets remain stable when maintained below
the lipid transition temperature even after the removal of the alcohol due to the inability of the
lipids to flow and assume a new formation. When heated above the transition temperature,
however, the lipid bilayer transitions to a liquid crystalline phase (Lα) [134]. As the membrane
becomes more fluid, the sheets will refold into spherical vesicles.
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Figure 20. SUV's before (A and B) and after (C and D) the addition of alcohol. Upon alcohol addition, the
solution becomes opaque and white, accompanied with a large increase in viscosity. The vial was tipped on its
side in images B and D to demonstrate this increase in viscosity.

eLiposomes were formed by heating sheets in the presence of emulsion droplets (see
Figure 1). During heating and stirring, the gel-like sheet solution decreased in viscosity as the
lipid sheets were heated above their transition temperature, became more fluid and refolded into
vesicles. Resulting vesicles typically had average diameters greater than 1 µm and very broad
size distribution as observed by DLS and by light microscopy. Although some vesicles reformed
at sizes as small as 250 nm, others formed at much larger sizes, sometimes as large as 5 to 20
µm. The eLiposomes were resized by extrusion through an 800-nm polycarbonate filter. Figure
21 shows the DLS data from a typical sample of extruded eLiposomes. There are two peaks
present, one of which is assigned to the emulsion droplets (130 nm) and the other to the lipid
bilayer vesicles (795 nm). The emulsion size before mixing with the lipid sheets was 120 nm.
The eLiposome peak in this example ranges from 400 to 1200 nm, with a median diameter of
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795 nm. This experiment was repeated 10 times with the lipid peak having an average median
size of 869.84±102 (standard deviation) and the emulsion peak having an average median size of
123±38. This demonstrates the ability to resize the eLiposomes after they have encapsulated
emulsion droplets.

This is crucial because of the large average diameter and wide size

distribution observed after sheet heating and vesicle formation. The ability to reduce the average
diameter and narrow the size distribution is crucial in order to take advantage of the EPR effect.
While the average diameter of the outer eLiposome membrane was slightly larger than the filter,
the average size of the vesicles was significantly reduced compared to before extrusion and
controlled to a size near the filter size. The slight descrepency in filter size and vesicle diameter
could be due to the relatively large filter size being used, allowing for some motion and
flexibility as the vesicles are forced through the filter.

Figure 21. Typical DLS data from an eLiposome sample after extrusion through an 800 nm filter. The peak
at 130 nm is assigned to emulsion droplets. The peak at 795 is assigned to the outer lipid membrane.
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6.3 TEM imaging of eLiposomes
6.3.1 Negative staining
eLiposomes were imaged by TEM using negative staining to verify the formation of
closed vesicles. Negative staining images are presented in Figure 22 and Figure 23. The sample
preparation process may have altered the appearance of these lipid structures; folds and creases
in the surface of the membrane may have formed as the sample dried. Alternately, some of these
creases and folds could be the result of lipid sheets that did not completely refold and recombine.
Regardless, the images confirm the closed 3-dimensional structure of the lipid membranes. This
is an important point as it provides evidence that our refolding technique via heating was able to
form new vesicles from lipid sheets. The TEM images also show that at least some of the
refolded lipid vesicles are multilamellar (See Figure 22). The negative staining images also
showed emulsion droplets (distinguished by smooth edges and smaller size).

Figure 22. Examples of eLiposomes as imaged with negative staining. These images show the closed vesicles
formed from lipid sheets during the reheating step. It can also be observed that at least some of these vesicles
are multilamellar.
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Figure 23 shows examples where emulsion droplets - the smaller structures from 50-150
nm - were observed as well. Some of these emulsion droplets are indicated with black arrows.
These TEM images also confirm sizes measured by DLS; the negative staining images confirm
the presence of 400-800 nm vesicles. While negative staining was useful for showing the
structure of eLiposome vesicles, it could not conclusively show droplet encapsulation. While
there are some droplets that appear to be inside of the membrane, their location is inconclusive
do to the nature and limitations of the staining and drying process.

Figure 23. Several examples of eLiposomes imaged with negative staining. The images show the variety of
vesicle diameters and appearances as observed by TEM. Emulsion droplets - the small round structures
from 50 to 150 nm - were observed as well. Some of these emulsion droplets are indicated with black arrows.
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6.3.2 CryoTEM imaging of eLiposomes
Figure 24 shows images of eLiposomes obtained by cryoTEM. The eLiposomes in
Figure 24A-F were prepared using an emulsion with an average diameter of about 100 nm. The
eLiposome in Figure 24G-I was prepared with an emulsion with an average diameter of about
475 nm.

Emulsion droplets that were observed with cryoTEM retained the 3 possible

appearances discussed previously (Chapter 5.4). Namely, they either appeared as dark electron
dense spots, as very light spots or as a dark circle surrounding a lighter one.
Cryo-TEM allows the viewing of unstained specimens that are embedded in a layer of
vitreous (non-crystalline) ice. Internal as well as external features can be seen because the
method relies on the inherent contrast within the specimen, not on contrast provided by an
applied stain. The fibrous structures in Figure 24 are the carbon-formvar support that lies on the
copper grid and supports the vitreous ice layer. The micrographs show an outer lipid membrane,
and emulsion droplets encapsulated inside of the membrane. In order to verify that the emulsion
droplets were truly encapsulated, the microscope stage was rotated to -45°, 0°, and +45° to verify
that the images of the emulsion droplets remained enclosed within the image of the lipid
membrane.
Figure 24A-C shows an example of a 600-nm eLiposome containing 3 emulsion droplets
ranging from 100 to 150 nm in size. As the stage is rotated through 90°, the images of these
droplets remain inside of the liposomal boundary. Likewise, Figure 24D-F shows an example of
a 500-nm eLiposome with two large emulsion droplets as well as a number of smaller emulsion
droplets.

This eLiposome also has additional polygonal structures encapsulated.

These

structures are most likely additional DPPC vesicles of various sizes that may have collapsed.
Rotation of the microscope stage again demonstrates encapsulation of these structures inside of
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the liposomal membrane. The sheet refolding technique showed the ability to encapsulate both
large and small emulsion droplets as shown in Figure 24. Figure 24G-I shows an example of an
800-nm eLiposome with one 475-nm emulsion droplet as well as two smaller droplets.

Figure 24. eLiposomes with encapsulated emulsion droplets imaged via cryoTEM. The microscope stage was
rotated to -45° (A, D, and G), 0° (B, E, and H), and +45° (C, F, and I) to demonstrate encapsulation of
droplets.
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Freezing samples for cryoTEM and rotating the stage allowed a unique and novel method
to verify encapsulation of the emulsion droplets. Being able to view the droplets inside of the
eLiposome membrane at various angles provides solid proof of their encapsulation. In contrast,
Figure 25 shows examples of non-encapsulated structures that appear to be inside of the
liposome boundary until the stage is rotated. The arrows in Figure 25 identify droplets that
might appear to be encapsulated. When rotated by 45°, however, these droplets can be observed
to be outside of the membrane, and thus are not encapsulated.

Figure 25. Cryo-TEM image of an eLiposome with internal and external emulsion droplets, as shown by
rotating the microscope stage by 45°. The arrows in the left panel point to specific droplets that appear to be
encapsulated (top arrow) or unencapsulated (bottom arrow). However, when rotated by 45° (right panel),
both droplets are clearly outside of the membrane.

Figure 26 shows examples of control lipid vesicles, made by refolding lipid sheets
without emulsion present. The appearance of the lipid membranes can be observed, as well as
the absence of emulsion droplets that were present in the eLiposomes of Figure 24 and Figure
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25. Similar to the structures observed in Figure 24D-F, there are again additional polygonal
structures.

Their presence in the absence of emulsion supports the possibility that these

structures are DPPC vesicles that have partially collapsed and become polygonal.

Figure 26. CryoTEM images of empty liposomes formed by refolding DPPC sheets without any emulsion
present.

6.4 Ultrasound induced release of calcein from eLiposomes at 20 kHz
In order to test their efficacy as ultrasound-sensitive drug carriers, eLiposomes were
exposed to 20 kHz ultrasound and compared to controls of conventional liposomes with and
without external emulsion droplets. Concentrated (self-quenched) calcein was encapsulated
inside of eLiposomes and some of the excess was removed from the outside so that the interior
calcein would not add to the fluorescent signal generated by the solution. The eLiposome
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sample was then diluted in a cuvette to create a system in which calcein released from the
eLiposome would be detectable by a fluorometer and in which the released calcein would fall
within the linear range of the fluorescence versus concentration plot for calcein.

20-kHz

ultrasound was chosen in order to employ an acoustic system using a small-diameter tipped
probe sonicator. This allowed the application of ultrasound within an optical cuvette. While
ultrasound from a probe sonicator would not be used in a clinical setting due to focus and
potential safety limitations, the work performed at 20 kHz has provided meaningful insights into
the behavior of eLiposomes compared to conventional liposomes when exposed to ultrasound.
Short exposure times and relatively low intensities were chosen in order to provide ultrasound
exposures that would be comparable to higher frequency ultrasound administered in short pulses
over a longer period of time.

Most ultrasound parameters that were used correspond to

mechanical indices below the FDA approved limit of 1.9. Acoustic droplet vaporization of
perfluorocarbons has been reported by others at higher frequencies and similar mechanical
indices [44, 45, 56]. In some cases higher intensities were employed in order to explore the
behavior of eLiposomes and conventional liposomes at higher intensity.

6.4.1 Release at 20 kHz and short exposure times
When exposed to 20-kHz ultrasound for short exposure times, eLiposome samples
demonstrated an increase in calcein release compared to controls. Figure 27 shows the percent
released after 100 milliseconds (ms) of exposure to 20-kHz ultrasound (n= 3, and error bars
represent one standard deviation). Ultrasound intensity was varied between 0.5 W/cm2 and 5
W/cm2. eLiposomes were prepared with large (450 nm) and small (100 nm) emulsion droplets.
The amount of release increased as ultrasound intensity increased. After 100 ms of ultrasound
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exposure, PFC5 eLiposomes released approximately 3 to 4 times more calcein than controls at
each intensity (Figure 27A). For example, at 5 W/cm2 eLiposomes with large PFC5 emulsion
droplets released 39% and eLiposomes containing small PFC5 emulsion droplets released 31%,
while control samples released only 10% of the encapsulated calcein.

Figure 27. Calcein release from PFC5 eLiposomes (A) and PFC6 eLiposomes (B) when exposed to 100
milliseconds of 20-kHz ultrasound at varying intensities. Data is presented for eLiposomes with large () and
small () emulsion droplets, control vesicles without emulsion (), and control vesicles with large () or
small () emulsion droplets added to the exterior solution. Error bars represent ± 1 standard deviation.

PFC6 eLiposomes also released more of the encapsulated calcein than control samples.
Figure 27B shows calcein release from PFC6 eLiposomes after 100 ms of insonation. While this
release was slightly less than observed from PFC5 eLiposomes, PFC6 eLiposomes also released
up to 3 times more calcein than control samples. After 100 ms at 5 W/cm2, eLiposomes with
100-nm PFC6 emulsions released 22% of the available calcein. The difference in calcein release
between controls and eLiposomes was statistically significant (Student t-test, p < 0.05) for both
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PFC5 eLiposomes with both large and small emulsion droplets and PFC6 eLiposomes with large
droplets.
Negative controls included both empty vesicles and empty vesicles with emulsion
droplets added to the exterior. All of these negative controls released less of their encapsulated
calcein than eLiposome samples. At 100 ms of ultrasound exposure there was no significant
difference (p > 0.05) between empty control liposomes and empty liposomes with emulsion
droplets added to the outside solution, regardless of emulsion size or material (see Figure 27).
There was, however, more variability in samples with emulsion droplets added to the outside of
the vesicles; empty vesicles had an average standard deviation of 3% compared to a standard
deviation of 5% when emulsion droplets were added to the exterior solution (n=3). There was no
significant difference (p > 0.05) between release from empty vesicles with small exterior droplets
and release from empty vesicles with large exterior droplets.
After 100 ms of ultrasound exposure, the difference in calcein release from eLiposomes
with large PFC5 emulsion droplets was statistically significant (p < 0.05) compared to
eLiposomes with small droplets at intensities of 2 W/cm2 or greater. In PFC6 samples exposed
to 100 ms of ultrasound, the difference in calcein release from eLiposomes with large emulsion
droplets was statistically significant compared to eLiposomes with small droplets at intensities of
3 W/cm2 or greater.

6.4.2 Release at 20 kHz with longer exposure times
Although there was an increase in calcein release from eLiposomes compared to
conventional liposomes after 100 ms, there was still a significant portion of the encapsulated
calcein that was not released. While in theory droplet vaporization and associated drug release
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could occur within the first few ultrasound cycles, there may be factors that delay ultrasoundinduced release from eLiposomes. For this reason, calcein release at longer exposure times was
also investigated. Because the motivation behind eLiposomes is to release a large amount of the
encapsulated load at mild ultrasound parameters, exposure times were maintained relatively short
(10 seconds and less). The objective of these experiments was to investigate a) if the time of
exposure has a significant effect on release and b) if a majority of encapsulated calcein can be
released from eLiposomes while maintaining mild ultrasound intensities and energy exposures.
The effect of time was investigated by varying the length of ultrasound exposure from
100 ms to 10 seconds for eLiposomes and control samples. This was performed at 0.5, 1, and 2
W/cm2 (MI = 0.87, 1.22, and 1.73).

Each data point presented is the mean of three

measurements. Longer exposure times at higher intensities were not explored because the
mechanical index would be greater than 1.9. Not only is this the limit imposed by the FDA, but
these higher intensities would be more likely to produce significant heating and tissue damage at
long exposure times.
eLiposomes containing large PFC5 emulsion droplets released the majority of their drug
load when exposed to ultrasound for 10 seconds (see Figure 28). Samples exposed to 0.5, 1, and
2 W/cm2 for this length of time released 75%, 94% and 94% of their drug load, respectively.
This was much more release than observed in control samples, which released approximately
15%, 20% and 30% at these intensities. Furthermore, this release was quite rapid, with the
majority of release taking place within the first 5 seconds of ultrasound exposure at all 3
intensities. While exposure at 2 W/cm2 did not produce additional release after 10 seconds of
exposure when compared to 1 W/cm2, it should be noted that the amount of release after 1 and 5
seconds was significantly greater at the higher intensity. It should also be noted that although

92

PFC5 eLiposome samples with large droplets approached 100% release with these relatively
mild ultrasound parameters, other eLiposome configurations did not.

Figure 28. Calcein release from PFC5 eLiposomes when exposed to 20-kHz ultrasound at 0.5, 1 or 2 W/cm2
for varying times. Data is presented for eLiposomes with large () and small () emulsion droplets, empty
control vesicles (), and empty vesicles with large () or small () emulsion droplets added to the exterior
solution. Sham experiments (no ultrasound) were also performed using eLiposomes with large droplets ().
Error bars represent ± 1 standard deviation.

While the size of the emulsion droplets had only a small effect at 100 ms of ultrasound
(Figure 28), this effect became more pronounced with PFC5 eLiposomes at longer ultrasound
exposures; eLiposomes with large emulsion droplets released approximately twice as much
calcein as those with small droplets after 10 seconds of ultrasound exposure at all three
intensities tested. PFC5 eLiposomes with 450-nm emulsion droplets released approximately
75% of encapsulated calcein after 10 seconds of 0.5 W/cm2 ultrasound while PFC5 eLiposomes
with 100-nm droplets released only 33% after 10 seconds (Figure 28A).

Similarly, PFC5

eLiposomes with 450-nm emulsion droplets released approximately 94% of encapsulated calcein
after 10 seconds of 1 W/cm2 or 2 W/cm2 ultrasound while PFC5 eLiposomes with 100-nm
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droplets released only 47% (Figure 28B and 28C). These differences between calcein release
from eLiposomes with large PFC5 emulsion droplets and calcein release from eLiposomes with
small PFC5 emulsion droplets were significant at all time points for samples exposed to 2
W/cm2. The differences were significant for samples exposed to 1 W/cm2 for 1 second or longer
and for samples exposed to 0.5 W/cm2 for 5 seconds or longer. Although not as much calcein
release was observed from eLiposomes containing small droplets, this release was still
significantly higher than control samples at every time point for each intensity.
The difference in release from eLiposomes with droplets of different sizes is most likely
due to the additional Laplace pressure on the smaller droplets (see Chapter 5.1). At 0.5 W/cm2,
the ultrasound imposes a negative pressure of 122 kPa, sufficient to overcome the difference in
the atmospheric pressure and the vapor pressure of PFC5 (see Table 1). This amplitude is also
sufficient to overcome the Laplace pressure of approximately 36 kPa on a 450-nm droplet.
However, this amplitude is not sufficient to overcome the Laplace pressure of approximately 160
kPa on a 100-nm droplet. At this smaller size 1 W/cm2 is required to overcome the additional
Laplace pressure, with ultrasound at this intensity imposing 173 kPa of negative pressure. The
large difference observed in calcein release from eLiposomes with large and small droplets at 1
W/cm2 and 2 W/cm2 indicates that either additional pressure beyond the theoretical requirements
is required to vaporize the droplets, or that a more consistent or violent vapor expansion may
occur from the larger droplets.
Figure 29 shows the amount of calcein release from PFC6 eLiposomes at times varying
from 100 ms to 10 seconds. PFC6 eLiposomes released more than controls with increasing time.
At 0.5 and 1 W/cm2, eLiposomes released approximately 2 times as much calcein as controls.
Although the increase in release was much less than observed in PFC5 samples, these differences
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were statistically significant (p < 0.05). At 2 W/cm2, however, only eLiposomes with large
PFC6 emulsion droplets showed a significant increase in calcein release compared to controls,
with eLiposomes releasing about 1.5 times as much calcein. Calcein release from eLiposomes
with small PFC6 droplets was not statistically different than control samples.

Figure 29. Calcein release from PFC6 eLiposomes when exposed to 20-kHz ultrasound at 0.5, 1 or 2 W/cm2
for varying times. Data is presented for eLiposomes with large () and small () emulsion droplets, empty
control vesicles (), and empty vesicles with large () or small () emulsion droplets added to the exterior
solution. Sham experiments (no ultrasound) were also performed using eLiposomes with large droplets ().
Error bars represent ± 1 standard deviation.

As intensity was increased from 1 W/cm2 to 2 W/cm2, there was no significant change in
the amount of calcein released from any of the eLiposome samples. However, all control
samples (both empty and with external emulsion) showed a statistically significant increase in
calcein release at 10 seconds of ultrasound when the intensity was increased from 1 W/cm2 to 2
W/cm2. Similar to results shown in Figure 27, control samples with external emulsion droplets
released the same average amount as empty negative controls, but showed more variability.
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In contrast to PFC5-containing eLiposomes, there was no difference in calcein release
from PFC6 eLiposomes with small droplets compared to those with large droplets when exposed
to 0.5 W/cm2 ultrasound (Figure 29A). There was, however, a statistical difference in PFC6
eLiposomes with small and large droplets when exposed to 1 W/cm2 or 2 W/cm2 for 5 seconds or
longer (Figure 29B and 29C). While there was a statistical difference between these samples, the
difference was much less pronounced than it had been with PFC5 eLiposomes. For example,
after 10 seconds of exposure to 0.5, 1, and 2 W/cm2, eLiposomes containing 450-nm PFC6
droplets released 31%, 45% and 47% of the encapsulated calcein, respectively. In comparison,
eLiposomes with 100-nm PFC6 droplets released 31%, 34%, 36%.
Sham experiments were also performed to verify that the laboratory manipulations and
procedures were not responsible for the observed calcein release.

eLiposomes with large

emulsion droplets were submitted to the entire release procedure, including insertion of the probe
into the cuvette for the same amount of time as active experiments. These sham experiments
showed no evidence of payload leakage or eLiposome damage from the experimental procedure
(see Figures 28 and 29).

The sham experiments suggest not only that the calcein release

reported was not induced by the experimental procedure, but also seem to indicate that the
eLiposomal membrane and structure are sufficiently robust to sequester a drug load despite
various steps of manipulation and handling.
In order to verify that temperature was not playing a significant role in calcein release,
the temperature of the solution was measured after sonication using a thermocouple.

The

temperatures of samples exposed to 2 W/cm2 for 10 seconds increased by an average of
approximately 4°C and those of samples exposed to 2 W/cm2 for 5 seconds increased by
approximately 2°C.

Increased temperature was not measureable in other samples at lower
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intensities and times. Because the resulting temperatures were still well below the transition
temperature for DPPC and below the temperature at which the nano emulsions were extruded
(50°C), it is unlikely that the increase in temperature was responsible for the increase in calcein
release from eLiposomes or from control samples.
In summary, it was found that eLiposomes did release additional calcein with increasing
ultrasonic exposure. This may partly be explained by the experimental setup; it is likely that
there are regions of the cuvette, such as the sides and corners, where the effective ultrasound
intensity is significantly lower than it is near the tip of the ultrasound probe. This would mean
that eLiposomes in the low-exposure regions would require ultrasound-induced convection in the
cuvette in order to be fully exposed to ultrasound; without full exposure to ultrasound at the
expected intensity, eLiposomes may not release their contents. Therefore, the time necessary for
mixing would increase to the amount of time required to observe full release. In order to test the
rate of mixing, a small drop of calcein solution was carefully added to a corner of the cuvette and
sonicated at intensities from 0.5 W/cm2 to 5 W/cm2. The amount of time required for the dye to
mix throughout the cuvette and for the solution to become uniform in color was measured. At
0.5 W/cm2, the dye was fully mixed through the cuvette after approximately 1.8 seconds. At 1
W/cm2, the dye had mixed through the cuvette after approximately 0.5 seconds. Mixing at
higher intensities was too rapid to measure. Therefore, the initially slower release at 0.5 W/cm2
may have been, in part, due to inadequate mixing, but this is unlikely to have had a significant
effect at longer times or at higher intensities. At times or intensities where there was inadequate
mixing, it is possible that some vesicles were not exposed to full-intensity ultrasound because of
the use of a continuous wave. In order to consider this possibility, large PFC5 and PFC6
eLiposomes were exposed to 100 ms bursts of 0.5 W/cm2 and 1 W/cm2 ultrasound at 1 Hz for 10
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seconds, so that the overall exposure was equal to a single 1 second exposure. During the period
where the ultrasound was “off” between the short bursts of ultrasound, the solution would have
continued to mix, but overall ultrasound exposure was the same. Results from this comparison
are presented in Table 3. Despite allowing more complete mixing in the pulsed sample, there
was not a significant difference in calcein release between the pulsed sample and the continuous
sample, suggesting that mixing did not have a large effect and the ultrasound may have
efficiently induced release throughout the entire cuvette. Other effects, such as delayed vapor
nucleation, likely play a role in the time-dependency of release.

Table 3. Large PFC5 and PFC6 eLiposomes were exposed to 1 second of 20-kHz ultrasound at
0.5 W/cm2 and at 1 W/cm2. The ultrasound was delivered continuously in some
samples. Other samples were exposed to 10 bursts of 100 ms at a 1 Hz
pulse repetition frequency. All values reported are the mean
of 3 measurements ± 1 standard deviation.

2

0.5 W/cm
1 W/Cm2

Continuous
20 ± 4%
44 ± 5%

PFC5

Pulsed
23 ± 4%
43 ± 5%

Continuous
11 ± 6%
22 ± 5%

PFC6

Pulsed
14 ± 3%
21 ± 4%

It is also interesting that the amount of release often seemed to level off as time
increased, especially at the higher intensities tested. For example, PFC5 eLiposomes with 100
nm emulsion droplets released 43% of encapsulated calcein in the first 5 seconds of ultrasound
exposure, and only released an additional 4% with 5 seconds more of ultrasound. Similarly,
negative controls released an average of 15% of encapsulated calcein in the first 5 seconds of
ultrasound exposure, followed by only 4% additional release in the last 5 seconds of ultrasound.
This suggests that an equilibrium point exists for both conventional liposomes and eLiposomes
where increased time of exposure will not increase drug release. It is especially important that
for most eLiposome samples, this leveling-off occurred well before 100% release.
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This could

be due to eLiposomes that did not initially contain emulsion droplets or due to a portion of the
population from which emulsion droplets had escaped or dissolved away prior to complete
membrane rupture and drug release. Either of these scenarios would lead to an intermediate
level of release that is less than 100%, but more than that observed in control samples. As an
additional explanation, there could be some eLiposomes that contain only very small emulsion
droplets that, due to increased Laplace pressure, fail to vaporize at the ultrasound parameters
applied.

6.4.3 Effect of eLiposome size
The eLiposomes described to this point have a diameter cutoff of approximately 800 nm.
Eventually, in order to best take advantage of the EPR effect, eLiposomes will have to be formed
with vesicle diameters between 150 and 300 nm. This lower range of sizes would help allow
penetration of the eLiposomes into leaky tissues (such as cancerous tumors). Literature also
suggests that the smaller vesicles may be internalized more readily into cells themselves.
eLiposomes containing small-diameter emulsion droplets (75-100 nm) were extruded through
200 nm filters in order to explore the possibility of forming smaller eLiposomes. DLS confirmed
that the resulting eLiposomes typically had average diameters of approximately 150-250 nm.
Figure 30 shows an example of the data collected by DLS. In this example there are two distinct
peaks, with the peak at 200 nm attributed to the outer membrane of the eLiposomes and the peak
at 80 nm attributed to emulsion droplets. However, in contrast to the larger eLiposome samples,
there were not always two obvious peaks when eLiposomes were extruded through 200 nm
filters. Some samples had a bimodal distribution, while others did not. Those that did not often
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had a very wide distribution.

This is perhaps due to the DLS algorithm being unable to

differentiate two distributions that are close to each other.

Figure 30. Typical DLS data from an eLiposome sample after extrusion through a 200 nm filter. The peak at
80 nm is assigned to emulsion droplets. The peak at 200 nm is assigned to the outer lipid membrane.

Figure 31A shows the amount of calcein released from 200 nm eLiposomes after 100
milliseconds (ms) of exposure to 20-kHz ultrasound. Each data point represents the average of 3
repeated experiments. Ultrasound intensity was once again varied between 0.5 W/cm2 and 5
W/cm2. In contrast to results with large eLiposomes samples (Chapter 6.4.1), there was not a
significant difference in release from small PFC6 eLiposomes and small PFC5 eLiposomes after
100 ms of ultrasound exposure.

After 100 ms at 5 W/cm2, small eLiposomes released

approximately 13% of the available calcein regardless of perfluorocarbon liquid, while control
liposomes released approximately 4% of their calcein. The difference in calcein release between
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controls and eLiposomes was statistically significant (Student t-test, p < 0.05) for both PFC5 and
PFC6.

Figure 31. A) Calcein release from conventional DPPC liposomes () and from 200 nm eLiposomes formed
with PFC5 () and PFC6 () when exposed to 20 kHz ultrasound for 100 ms. B) Comparison of calcein
release from large (800 nm) vesicles and from small (200 nm) vesicles after 100 ms of exposure to 20 kHz
ultrasound at 5 W/cm2.

Figure 31B provides a comparison between calcein release from large (800 nm) vesicles
and small (200 nm) vesicles at 100 ms exposure time and 5 W/cm2. All eLiposomes samples
used for this comparison were prepared with 100 nm emulsion droplets. Small eLiposomes
released less of the encapsulated calcein than their large counterparts. Large PFC5 eLiposomes
with small droplets released 31% of the encapsulated calcein, while small PFC5 eLiposomes
released 13%. Similarly, large PFC6 eLiposomes released 22% of the encapsulated calcein,
while small PFC6 eLiposomes released 13%. The decrease in release was also consistent for
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conventional liposome controls; large control liposomes also released more than small liposomes
(10% and 4%, respectively).
This decreased ability of small eLiposomes to release their encapsulated load is also
apparent with increased exposure times. Large PFC5 eLiposomes with small emulsion droplets
exposed to 0.5, 1, and 2 W/cm2 for 10 seconds released 33%, 47%, and 47% of their drug load,
respectively (see Figure 28). In contrast, the amount of release from small PFC5 eLiposomes
exposed to 0.5, 1, and 2 W/cm2 for 10 seconds was approximately 18%, 25% and 27% (See
Figure 32).

Figure 32. A) Calcein release from 200 nm PFC5 eLiposomes (solid symbols) and from conventional DPPC
liposomes (empty symbols). 20-kHz ultrasound was applied at 0.5 W/cm2 (blue squares), 1 W/cm2 (green
triangles) and 2 W/cm2 (red circles). B) Calcein release from 200 nm PFC6 eLiposomes and from
conventional DPPC liposomes. C) Comparison of calcein release from large (800 nm) vesicles with small
emulsion droplets and from small (200 nm) vesicles after 10 seconds of exposure to 20-kHz ultrasound at 1
W/cm2.

Figure 32A shows the amount of calcein release from small PFC5 eLiposomes at 0.1, 1,
5, and 10 seconds. Once again, the amount of release from eLiposomes increased with time.
Ultrasound was applied at intensities of 0.5, 1, and 2 W/cm2. As would be expected, release also
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increased with intensity. At 1 and 2 W/cm2, calcein release was quite rapid, with the majority of
the released calcein escaping within the first 5 seconds. At 0.5 W/cm2, release was more gradual
and continued to increase significantly through 10 seconds. Control vesicles released much less
of their encapsulated calcein compared to eLiposomes samples. Interestingly, there was no
significant difference in small control samples exposed to 0.5, 1 or 2 W/cm2 after 10 seconds,
with all of these controls releasing approximately 5% of the encapsulated calcein. Furthermore,
calcein release from small control liposomes seemed to have leveled off between 1 and 5
seconds.
While there was no difference between small PFC5 and PFC6 eLiposomes at short times
(Figure 31), this difference was again apparent at longer times (see Figure 32). For example,
while small eLiposomes containing PFC5 droplets released 18%, 25% and 27% of encapsulated
calcein after 10 seconds of ultrasound at 0.5, 1 and 2 W/cm2, small eLiposomes with PFC6
droplets released 13%, 17%, and 24% at these same intensities (see Figure 32B).
Similar to results at short times, small vesicles released less of the encapsulated calcein
than large vesicles containing small emulsion droplets (see Figure 32C). At 10 seconds of
exposure to 1W/cm2 ultrasound, large PFC5 eLiposomes with small droplets released 47% of the
encapsulated calcein, while small PFC5 eLiposomes released 25%.

Similarly, large PFC6

eLiposomes released 34% of the encapsulated calcein, while small PFC6 eLiposomes released
17%. Large control liposomes also released more than small liposomes at an exposure time of
10 seconds (19% and 6%, respectively).
Because small conventional liposomes also released less than their large counterparts,
there was still a significant increase in release from small control liposomes to small
eLiposomes. In some cases, this increase was more substantial than this comparison at large
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vesicle sizes. After 100 ms of ultrasound exposure small eLiposomes with PFC5 or PFC6
released approximately 3 to 5 times more calcein than control samples at the intensities tested
(Figure 31A). Interestingly, this ratio is the same as was observed with large eLiposomes with
short exposure times. After 10 seconds at 1 W/cm2, small PFC5 eLiposomes released 3 to 6
times as much calcein as controls and small PFC6 eLiposomes released 2 to 4 times as much
calcein compared to controls. Because the motivation for producing smaller vesicles would be to
take advantage of the EPR effect, comparisons among samples of similar size are perhaps the
most relevant comparisons.
It is interesting that size has a significant effect on release from both the eLiposome and
control liposome samples. This tendency of small liposomes to be less-susceptible to ultrasound
than larger liposomes has been previously documented [80, 135]. While the role that size plays
on the interactions between ultrasound and liposomes is not fully understood, it has been
hypothesized that smaller liposomes lack the ability to elongate and break up when exposed to
the shear forces provided by cavitating bubbles [86]. This previously observed phenomenon
may play a role in the decreased release from eLiposomes at smaller sizes. However, while this
is likely a contributing factor, it is possible that other factors play a role as well. For example,
smaller vesicles will have fewer encapsulated emulsion droplets and therefore the inability of
encapsulated droplets to combine into larger droplets or bubbles

6.4.4 Effect of temperature
In order for emulsions and eLiposomes to be useful as drug delivery vehicles, their
stability and behavior at 37°C (biological temperature) must also be explored. As mentioned
previously, emulsion droplets persisted despite being heated during processing.
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While

occasional foaming did occur when heating to 50°C for extrusion, this foaming was limited and
controlled by allowing the extruder to cool before removing the syringes. The persistence of
emulsion droplets was verified by centrifuging the solution on a sucrose cushion and observing
the collection of a pellet below the dense sucrose phase. Because eLiposome stability at 37°C is
of particular interest, the stability and ability to sequester calcein at 37°C was examined with
fluorometry. It was determined that approximately 3 minutes were required to warm the solution
to 37°C in a water bath. eLiposome samples were diluted in 2 mL of buffer solution as described
in Chapter 4.2.8. The fluorescence was measured initially after dilution and the sample was
placed in a heated water bath for 3 minutes. After 3 minutes, no evidence of calcein release
could be observed. The sample was heated and fluorescence was again measured after 10, 20,
and 30 minutes of heating. This process was repeated for large eLiposomes containing large
PFC5 or large PFC6 droplets and for small eLiposomes containing small PFC5 or small PFC6
droplets.

No significant amount of calcein release could be detected in any of these

measurements. The eLiposomes were lysed with Triton X-100 after the 30 minute fluorescence
measurement to verify the encapsulation of calcein. In all samples the fluorescence increased
with the addition of Triton X-100, indicating that the vesicles had remained intact and continued
to sequester calcein throughout the heating process.
Release experiments were repeated with heated samples. The optical cuvette was heated
in a 37°C water bath for 3 minutes and transferred to the fluorometer quickly to avoid cooling
before the measurement. After a 10 second baseline was collected, the sample was moved back
to the heated water bath and sonicated while being heated. Fluorescence was again measured
and the sample was lysed with Triton X-100 to measure 100% release. Figure 33A shows the
percent released from 800 nm eLiposomes with large emulsion droplets after 100 milliseconds
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(ms) of exposure to 20-kHz ultrasound when heated to 37°C. Ultrasound intensity was once
again varied between 0.5 W/cm2 and 5 W/cm2. After 100 ms of ultrasound exposure at 5 W/cm2,
large PFC5 eLiposomes released approximately 49% of the available calcein and large PFC6
eLiposomes released 31%.

Large control liposomes released approximately 12% of their

calcein.

Figure 33. Calcein release at 37°C from 800 nm vesicles (A) and from 200 nm vesicles (B) exposed to 100 ms
of ultrasound at intensities from 1 to 5 W/cm2. Experiments were performed on PFC5 eLiposomes (), PFC6
eLiposomes () and conventional liposomes (). (C) Comparison of calcein release from eLiposomes and
control liposomes at room temperature (empty bars) and at 37°C (filled bars).

Figure 33B shows the percent released from 200 nm eLiposomes after 100 milliseconds
(ms) of exposure to 20-kHz ultrasound. While small eLiposomes at room temperature had not
shown a difference in release from PFC5 and PFC6 samples, this difference was again evident at
elevated temperature after 100 ms of ultrasound exposure. Small PFC5 eLiposomes released
approximately 15% of the available calcein and small PFC6 eLiposomes released 12%. Small
control liposomes released approximately 5% of their calcein. The difference in release between
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PFC5 and PFC6 eLiposome samples at 37°C was statistically significant for both large and small
vesicles (Student t-test, p < 0.05), as well as each eLiposome sample compared to control
samples.
Figure 33C compares the release of calcein from large or small vesicles at 37°C to release
at room temperature after 100 ms of exposure at 5 W/cm2.

Empty bars represent room

temperature release measurements and solid bars represent calcein release at 37°C. All reported
values are the average of three measurements and error bars represent ± 1 standard deviation.
There was not typically a significant increase in calcein release from the eLiposomes or from
conventional liposomes as temperature was increased from room temperature to 37°C. However,
the difference in release from large PFC5 eLiposomes was significant as temperature was
increased from room temperature to 37°C.

Figure 34. Calcein release from 800 nm vesicles (A) and from 200 nm vesicles (B) exposed to 1 W/cm2
ultrasound at 37°C. Exposure time was varied from 100 ms to 10 seconds. Experiments were performed on
PFC5 eLiposomes (), PFC6 eLiposomes (), and conventional liposomes (). (C) Comparison of calcein
release from eLiposomes and control liposomes at room temperature (empty bars) and at 37°C (filled bars).
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Figure 34A shows the percent of calcein released from 800 nm eLiposomes with large
emulsion droplets exposed to 1 W/cm2 ultrasound at 37°C. Exposure time was varied from 100
ms to 10 seconds. At 10 seconds, large PFC5 eLiposomes released approximately 93% of the
available calcein and large PFC6 eLiposomes released 47%. Large control liposomes released
approximately 24% of their calcein. Figure 34B shows the percent released from 200-nm
eLiposomes exposed to 20-kHz ultrasound at 1 W/cm2 at 37°C.

Despite the increased

temperature, small eLiposomes still released much less of their encapsulated calcein compared to
large eLiposomes (Figure 34A and 34B). Small PFC5 eLiposomes released approximately 32%
of the available calcein and small PFC6 eLiposomes released 17%. Small control liposomes
released approximately 8% of their calcein.
Figure 34C compares the release of calcein from large or small vesicles at 37°C to release
at room temperature after 10 seconds of exposure to ultrasound at 1 W/cm2; empty bars represent
room temperature release measurements and solid bars represent calcein release at 37°C.
Interestingly, after 10 seconds of ultrasound exposure at 1 W/cm2 there was little or no increase
in release at 37°C compared to room temperature in any of the samples. Only control liposomes
and small PFC5 eLiposomes released statistically more calcein at 37°C, and increases were
relatively small. While Figures 33C and 34C provide only a comparison at 5 W/cm2 after 100
ms and at 1 W/cm2 after 10 seconds, these results were typical for all data points collected;
generally, PFC5 eLiposomes released more calcein at the higher temperature while PFC6
eLiposomes did not. However, while these differences in release from PFC5 eLiposomes were
statistically significant, they were only noteworthy in large PFC5 eLiposome samples at short
exposure times.
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It is interesting that release did not increase more despite increasing temperatures.
Because increasing the temperature raises the vapor pressure of the perfluorocarbon liquids, the
ultrasound pressure requirements should decrease. The vapor pressure of PFC5 increases from
about 84 kPa to about 135 kPa, a 60% increase. The vapor pressure of PFC6 increases from
about 28 kPa to 48 kPa, a 79% increase.

At the increased temperature, lower ultrasound

intensities should be required to overcome the droplet vapor pressure and induce vaporization.
For example, at 24°C, ultrasound intensities of 0.5 and 1 W/cm2 are below the theoretical
threshold for vaporization of 100-nm droplets.

However, at 37°C, 1 W/cm2 is above the

theoretical threshold for vaporization. Also, the higher temperature was expected to increase
release even at other intensities tested due to a more substantial sub-pressurization that is
expected to aid in gas nucleation by increasing the thermodynamic potential for vaporization.
While the trends observed in the experimental results did somewhat mirror this hypothesis, the
increase in release was not as significant as expected. Furthermore, there was no obvious jump
in release from small droplets at 1 W/cm2 as the temperature increased. It is possible that the
lack of sharp thresholds and jumps in release is due to the size distribution of droplets.
Threshold calculations assume a homogeneous size, but there are larger and smaller droplets.
These droplets would therefore have different thresholds for vaporization and could result in the
observed lack of expected thresholds in the data. Once again, gas nucleation is a potential
limiting factor, and a comparison of short and long ultrasound exposures may suggest that the
time required to nucleate a gas is more important than providing additional driving force.

109

6.5 Ultrasound induced release of calcein from eLiposomes at 525 kHz
As mentioned previously, 20-kHz ultrasound would not typically be used in a medical
setting because low frequency ultrasound is more difficult to focus within the body and is often
cited as having health concerns [136-138]. The experiments at 20 kHz that are detailed in this
dissertation provide insight into eLiposome and emulsion behavior compared to conventional
liposomes when exposed to ultrasound. Furthermore, the results are relevant for research and
laboratory applications. Ultrasound parameters such as intensity, mechanical index, and energy
exposure were chosen to be comparable to medically relevant parameters.

However,

experiments at a higher frequency are also needed to verify the potential of eLiposomes to
release drugs at higher frequencies and to compare this release to comparable ultrasound
parameters at low frequency. It is expected that drug release will be similar at similar energy
exposures or at similar ultrasound intensities.
Ultrasound used in medical setting is typically 500 kHz and above; frequencies of 700
kHz to 3 MHz are used for therapeutic and drug delivery applications while frequencies above 1
MHz are used in imaging [139]. The HIFU transducer used in this study operates at 525 kHz.
At this frequency, ultrasound can be focused to a focal point of approximately 1.5 mm, making it
practical for clinical drug targeting applications. Short exposure times and/or pulsed ultrasound
were used in order to mimic medically relevant ultrasound parameters that would avoid heating
and tissue damage. Pulses of 1,000 cycles/pulse were applied at a pulse repetition frequency of
20 Hz. For some samples, single pulses of 50,000 cycles were used for short single burst
exposures.
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6.5.1 Exposure to 525 kHz at varying times and intensities
Release experiments were performed similar to those at 20 kHz.

However, after

collecting the initial fluorescence baseline, the sample was transferred to the bulb of a 3 mL
transfer pipet. The bulb containing the sample was placed at the focal point of ultrasound within
a water bath. Short exposure times and/or pulsed ultrasound were used to maintain similarity to
parameters typically used in medical applications to avoid heating and tissue damage.
Furthermore, it is likely that our experimental setup was prone to acoustic decoupling when
continuous wave ultrasound at high intensities was applied.
Figure 35 shows the amount of calcein release from small (200 nm) eLiposomes
containing PFC5 emulsions and control vesicles when exposed to 525 kHz ultrasound at 5
W/cm2 and 35 W/cm2. These intensities were chosen because the mechanical indices are low
enough to make these parameters medical relevant (MI = 0.53, and 1.41, respectively) and
relatively low intensity; the FDA allows ultrasound to be applied at mechanical indices up to 1.9.
Pulses of 1000 cycles were applied at a pulse frequency of 20 Hz. As mentioned in Chapter
5.5.2, acoustic decoupling was not detected at these parameters. The time of exposure was varied
from 2 seconds to 30 seconds, making the overall energy exposure relatively low.
The amount of release increased with exposure time, with PFC5 eLiposomes releasing
29% and 50% of the encapsulated calcein after 30 seconds of exposure to 5 W/cm2 and 35
W/cm2, respectively. In comparison, control liposomes released 14% and 16% of the calcein at
these same intensities. In general eLiposome samples released 2 to 3 times as much of their
encapsulated load compared to control vesicles when exposed to 5 W/cm2 and 3 to 3.5 times as
much of the calcein when exposed to 35 W/cm2.
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Figure 35. Calcein release from small (200 nm) PFC5 eLiposomes () and from control liposomes () at 525
kHz. Ultrasound was applied at 5 W/cm2 and at 35 W/cm2 in 1000 cycle bursts at a pulse frequency of 20 Hz.
Exposure time was varied from 2 to 30 seconds. Sham experiments were performed by exposing samples to
the complete procedure but without ultrasound exposure (). Each point represents the average of triplicate
measurements and error bars represent ± 1 standard deviation.

The differences between calcein released from eLiposomes compared to control samples
were significant at each point tested. The increase in calcein released from eLiposomes as the
intensity was increased from 5 to 35 W/cm2 was also significant at each point examined.
Interestingly, there was not a significant increase in calcein release from control vesicles as
ultrasound intensity was increased.
Sham experiments were also performed in which samples were handled the same as
active experiments, including the length of time that they were left in water bath, but without
ultrasound exposure (see Figure 35). Release from sham experiments was negligible.
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6.5.2 Effect of intensity at 525 kHz and comparisons to acoustic phenomena
In order to further explore the effect that intensity of 525 kHz ultrasound has on
eLiposomes, ultrasound intensity was varied from 5 W/cm2 to 425 W/cm2. The intensities tested
were chosen to examine the effect of intensity as well as to allow a comparison to the acoustic
phenomena described in Chapter 5.5.2. Figure 36 shows calcein release from PFC5 and PFC6
eLiposomes as well as control liposomes when exposed to 10 seconds of 525 kHz ultrasound at
5, 35, 150, and 425 W/cm2. At 5 W/cm2 and at 35 W/cm2, there was a significant contrast
between eLiposome samples and control samples, with eLiposomes releasing approximately 3
times as much of the encapsulated calcein. At 150 W/cm2, eLiposomes released only slightly
more calcein than controls (approximately 1.3 times as much); at 150 W/cm2, this difference was
only significant between PFC5 eLiposomes and conventional liposomes. At 425 W/cm2 there
was no significant difference in the release from eLiposomes and from control samples. It is
worth noting that the mechanical indices at 5 and 35 W/cm2 are within limits set by the FDA,
while 150 and 425 W/cm2 are beyond these limits.
Referring back to Figure 16, 5 W/cm2 is below the threshold for the detection of higher
harmonics. As these peaks are typically associated with stable cavitation of bubbles, the fact that
there is a significant increase in calcein release from eLiposomes compared to control liposomes
at this intensity suggests that droplet vaporization and expansion may begin to occur before
stable cavitation is detectable. At 5 W/cm2, both PFC5 and PFC6 are expected to be well beyond
the thresholds for vaporization based on their vapor pressures and the calculation of Laplace
pressure compared to ultrasound pressure amplitude (see Chapter 6.4.2). It appears from release
data at this intensity that vaporization is indeed occurring. This vaporization and expansion
could be partially or completely reversible and may not lead to a consistent cavitating bubble.
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Alternatively, bubble oscillations at this intensity could simply be below the thresholds for
detection of the higher harmonic peaks.

10 seconds
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Figure 36. Calcein release from small PFC5 eLiposomes (Red bars), PFC6 eLiposomes (blue bars), and
conventional liposomes (Green bars) as ultrasound intensity is increased from 5 to 425 W/cm2. Error bars
represent ± 1 standard deviation (n=3).

35 W/cm2 is above the threshold for higher harmonic peaks for both emulsion samples,
but below the threshold for water. The observation of these peaks in emulsion samples provides
evidence of persistent stable cavitation, suggesting that droplets have vaporized to form
persistent bubbles. The absence of higher harmonic peaks in the control samples at this intensity
(Figure 16) suggests that gas nucleation and cavitation does not occur in water at these
intensities. The fact that there is still a large difference in calcein release from eLiposomes and
control vesicles provides further evidence that the expanding and cavitating perfluorocarbon
phase is responsible for calcein release from eLiposomes. Furthermore, the difference in calcein
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release from eLiposome samples exposed to 5 W/cm2 and 35 W/cm2 is significant. This suggests
that the presence of a persistent gas phase and cavitation (as evidenced by the observation of
higher harmonic peaks in samples with emulsions) likely results in increased calcein release.
150 W/cm2 is above the threshold for higher harmonics in all samples and above the
threshold for the sub-harmonic peak in the emulsion samples. The presence of the higher
harmonic peaks in the control samples at this intensity seems to correlate well with a large
increase in release from the control samples (see Figure 36), suggesting that consistent cavitating
bubbles are formed at this intensity and contribute to calcein release from conventional
liposomes.

This result is in agreement with results at lower intensities in the eLiposome

samples; calcein release seems to be most strongly correlated with the expansion and cavitation
of a gas phase. As intensity was increased from 35 W/cm2 to 150 W/cm2 there was a slight
increase in release from eLiposome samples, suggesting that the onset of collapse cavitation
contributes only slightly to calcein release (sub-harmonic peaks were observed in emulsion
samples at 150 W/cm2, suggesting more chaotic cavitation and the onset of collapse cavitation).
The majority of the release seems to be correlated with the presence of a vapor phase, and is not
as strongly dependent on collapse cavitation.
Lastly, when ultrasound is applied at 425 W/cm2, which is above the thresholds for
collapse cavitation, there was no observable difference in release between samples. At this
intensity, all samples are expected to be well above the threshold for collapse cavitation. The
difference in release at 150 W/cm2 and 425 W/cm2 was only significant for PFC5 eLiposomes
and for control samples. Although significant, this increase in release was not as substantial as
increases between other intensities, especially for control samples.
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This evidence further

supports the hypothesis that while collapse cavitation may slightly enhance release from
liposomes, release is most strongly correlated with stable cavitation.

6.5.3 Effect of size at 525 kHz
It was previously reported that vesicle and emulsion size had a significant effect on
release from eLiposomes and conventional liposomes at 20 kHz. In order to determine if vesicle
size had a similar effect at 525 kHz, large (800 nm) eLiposome samples were prepared with
small (100 nm) emulsion droplets of both PFC5 and PFC6. Large control samples were also
prepared, and samples were exposed to 525 kHz ultrasound at 5 W/cm2 and 35 W/cm2 for 10
seconds. Figure 37 compares the release of calcein from these large vesicles to release from
small (200 nm) vesicles.

Figure 37. Comparison of calcein release from large (800 nm) and small (200 nm) eLiposomes and from large
and small control vesicles when exposed to ultrasound at 525 kHz.
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Similar to results at 20 kHz, the large eLiposomes released significantly more calcein
than their smaller counterparts. This pattern was consistent at 5 and 35 W/cm2. This increase in
release with vesicle size was slightly smaller at 525 kHz; large eLiposomes released 1.3 to 1.8
times as much calcein as small eLiposomes when exposed to 525 kHz compared to
approximately 1.6 to 2.4 times as much when exposed to 20 kHz. Large control vesicles also
released significantly more calcein than small control vesicles; large conventional liposomes
released 2 to 2.5 times as much calcein at 525 kHz compared to approximately 2.5 to 3.5 times
as much at 20 kHz.

6.5.4 Short exposure times and comparisons to lower frequency
Ultrasound at 525 kHz was also applied in a single burst of 50,000 cycles and at low
intensities in order to investigate the ability of short exposures (approximately 100 ms) at low
intensity to induce calcein release from the eLiposomes. These parameters also allow direct
comparison to calcein release at 20 kHz ultrasound with similar parameters.

Acoustic

decoupling was not detected from these single burst exposures; the short burst of ultrasound was
probably not enough time to form a field of bubbles.
Figure 38 shows calcein release from small PFC5 and PFC6 eLiposomes as well as
control liposomes when exposed to a single 100 ms pulse of 525-kHz ultrasound. There was a
significant increase in release from the control vesicles to eLiposome samples; PFC5
eLiposomes released approximately 5 times as much calcein compared to control liposomes and
PFC6 eLiposomes released approximately 4 times as much. The difference between calcein
release from eLiposome samples and control samples was significant at each intensity tested.
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Figure 38. Calcein release from small (200 nm) PFC5 eLiposomes (), PFC6 eLiposomes () and from
control liposomes (). 525 kHz Ultrasound was applied in a single 50,000 cycle burst and intensity was
varied from 0.5 W/cm2 to 5 W/cm2. Each point represents the average of triplicate measurements and error
bars represent ± 1 standard deviation.

While the difference in release from control vesicles to eLiposomes at short exposure
times was significant, the amount of release was relatively low. A single pulse of 100 ms at 525
kHz does not seem to be able to create a substantial amount of calcein release. For example,
PFC5 eLiposomes released only 6% of the loaded calcein when exposed to a single 100 ms burst
of ultrasound at 5 W/cm2. However, it does appear that calcein will continue to be released as
ultrasound is delivered in pulses; there was not a significant difference between calcein release
from eLiposomes exposed to 525 kHz ultrasound at 5 W/cm2 in a single 100 ms burst compared
to relatively similar ultrasound exposure times divided into 1000 cycle pulses.

This is

particularly relevant as short bursts are typically preferred in medical applications to limit
heating and tissue damage.
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Single short bursts (100 ms) of ultrasound were applied at 525 kHz at intensities at
mechanical indices of 0.87, 1.73, and 2.45. These mechanical indices correspond to those
employed at 20 kHz. Figure 39 provides a comparison of calcein release from eLiposomes when
exposed to 20 kHz and 525 kHz. When the ultrasound intensity and burst length was identical,
exposure to 20 kHz ultrasound produced significantly more release; on average, 2.5 times as
much calcein was released when exposed to 20 kHz compared to 525 kHz at the intensities
investigated. However, when the mechanical index was identical, there was no significant
difference in calcein release observed at the two frequencies. This occurred at all 3 values of
mechanical index.

Figure 39. Calcein release from small PFC5 eLiposomes when exposed to short (100 ms) exposure times of 20
kHz and 525 kHz at identical intensities and mechanical indices. Error bars represent ± 1 standard deviation
(n=3).
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Although the negative pressure corresponding to lower ultrasound intensities should, in
theory, be sufficient to overcome the vapor pressure of PFC5, the intensity of the 525 kHz
ultrasound had to be increased in order to produce similar release to that observed when samples
were exposed to 20 kHz ultrasound. This result provides further evidence that overcoming vapor
pressure is not the only relevant factor affecting drug release from eLiposomes. The ability to
nucleate a gas phase is likely a controlling factor in the droplet vaporization process. Low
frequencies of ultrasound have longer wavelengths, resulting in a longer period of low pressure
with each cycle. This longer period of low pressure may allow more time for nucleation and
expansion of a gas phase. Pitt, et al. developed a mathematical model of acoustic droplet
vaporization that describes a similar phenomenon; when the negative pressure applied by
ultrasound is held constant, the volume expansion of a vaporizing emulsion droplet is much
larger at lower frequencies due to the longer duration of the negative phase of the ultrasound
cycle [140]. Calcein release from eLiposomes suggests that the mechanical index, which was
developed to predict the likelihood of cavitation, may be a more effective way to account for the
effects of ultrasound applied at different frequencies.

6.6 Summary
eLiposomes released a higher percentage of encapsulated calcein than conventional
liposomes at all of the ultrasound parameters and exposure times tested. This release could be
observed at very short (100 ms) exposure times and increased with intensity. Release also
increased significantly as exposure time was increased.

This increased release with time

suggests that providing sufficient ultrasound pressure for vaporization is not the only parameter
that effects droplet vaporization. Other factors, such as the time required to nucleate a gas phase,
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likely play a significant role. In many cases, this increased release with increasing time had
leveled off or slowed down after about 5 seconds of ultrasound exposure for samples exposed to
20-kHz ultrasound.

A similar leveling-off was observed at 525 kHz as well.

There was

generally a significant increase in calcein release from eLiposomes containing PFC5 droplets
compared to those containing PFC6 droplets, probably due to the higher vapor pressure of PFC5.
Vesicle and emulsion droplet size also had a significant effect on calcein release.
eLiposomes containing large emulsion droplets released significantly more calcein than those
with small droplets. This difference can be attributed to the increased Laplace pressure on
smaller diameter droplets. The overall size of the vesicle also had a significant effect on calcein
release, with larger vesicles releasing significantly more calcein than small vesicles. This pattern
was observed in conventional liposomes as well as in eLiposomes.
Release experiments were also performed at 525 kHz, with eLiposomes once again
demonstrating increased calcein release compared to controls. While the patterns observed at 20
kHz remained consistent, eLiposomes and control vesicles released less calcein at the higher
frequency when intensity was maintained constant.

Interestingly, there was a stronger

correlation between mechanical index and release than between ultrasound intensity and calcein
release. This result supports the hypothesis that the rate of gas nucleation may be a limiting
factor in emulsion vaporization and subsequent calcein release even after a thermodynamic
potential for vaporization has been attained. Higher frequencies have shorter cycles of negative
pressure compared to lower frequencies, and therefore provide less time for a vapor phase to
nucleate with each cycle. When operating at high frequency, medium to long ultrasound pulses
administered at a relatively low pulse repetition frequency will probably be most efficient for
drug release; such parameters could provide sufficient time per pulse to encourage nucleation
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and still have a low time-averaged energy exposure. The amount of release would be expected
to continue to increase with each additional pulse until the ‘leveling-off” point mentioned above
had been reached. It is even possible that the increased opportunity for vapor nucleation with
each burst may increase this limit.
It was anticipated that increased temperatures would lead to increased calcein release due
to the resulting higher vapor pressures of the perfluorocarbon liquids. Unexpectedly, increasing
temperature resulted in only a small increase of drug release from most samples. While this
increase was usually statistically significant, it was not substantial.
Lastly, comparison of drug release to acoustic spectra (Chapter 5.5.2) suggests that
vaporization may induce release before sustained cavitation occurs; there was a significant
increase in release from eLiposomes compared to conventional liposomes at frequencies below
the threshold for higher harmonic peaks in the acoustic spectra.

There was a significant

additional increase in release from eLiposomes at intensities where stable cavitation had been
detected in emulsion samples, suggesting that the presence of a persistent and oscillating gas
phase adds to release from eLiposomes. The evidence of significant release from eLiposomes at
thresholds where persistent and violent bubble oscillations were not detected may indicate that
the mechanism of release could be largely correlated with increasing vapor volume that causes
holes or rips in the membrane (see Figure 19A). Although further increasing ultrasound intensity
did lead to an increase in calcein release from eLiposomes, this increase was relatively small.
Conventional liposomes followed this same trend; the most significant increase in calcein release
was observed at intensities that were correlated with stable cavitation. It should be noted that
although there was little or no difference between release from eLiposomes and conventional
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liposomes at high intensities, these intensities are well above acceptable ultrasound parameters
for clinical use.
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7

IN VITRO CELL STUDIES

eLiposomes and emulsions have advantages over other potential drug carriers due to the
ability to extravasate into tissues followed by ultrasound-mediated drug release. This strategy
may enhance drug targeting to tumors due to the combination of the EPR effect together with
ultrasound-mediated targeting. Many treatments, however, require therapeutic internalization
into cells in order to have their effect. Ideally, the drug carriers and ultrasonic targeting could be
used to not only penetrate tissues, but also to deliver drugs to the cell cytosol. Targeting ligands
can be attached to drug carriers in order to enhance their uptake into certain cells. For example,
in this study folate was attached to drug carriers because cancer cells typically overexpress the
receptors for folic acid. The binding of folate to these receptors induces endocytosis, thus
increasing uptake of the carriers into cancer cells relative to other cells. Drugs and drug carriers
are typically internalized into the cells via endocytosis. Because many molecules (for example,
nucleic acids) are digested in the resulting endosome, endosomal escape is an area of intense
research interest; in order to be effective, many therapeutics must be internalized into cells via
endocytosis, and then must escape the endosome before being digested.

An intriguing

application of emulsions and eLiposomes as drug carriers is the potential ability to break open
endosomal membranes. As the emulsion is vaporized and expands, this expanding vapor phase
may not only break open the eLiposomal membrane, but could also disrupt the endosomal
membrane and aid the escape of drugs or genes from the endosome.
124

7.1 Emulsions for endosomal release
Vaporizing emulsion droplets could be used to aid in endosomal escape by disturbing the
endosome as they expand. The emulsion could act as the drug/gene carrier itself, or be part of
another carrier such as an eLiposome. They could also be administered in combination with
other drug delivery vectors and techniques.
HeLa cells were grown in order to investigate the ability of nanoemulsions to disturb the
endosomal membrane when exposed to ultrasound. In order to encourage endocytosis of the
emulsions, cells were grown in folate free media.

Emulsions with average diameters of

approximately 200 nm were prepared with PFC5 and with PFC6. The emulsions were stabilized
with DPPC along with a small amount of DPPE-PEG2000-Folate. The emulsion was mixed 1:1
with concentrated calcein (30 mM). 200 µL of the resulting solution were added to HeLa cells
that had been grown in 1.3 mL of folate-free media, resulting in an approximate calcein
concentration of 4 mM around the cells. This concentration of calcein is sufficiently high to be
in the self-quenching range. The cells were allowed to incubate for 2 hours in this solution to
allow the emulsion and surrounding calcein-containing media to be endocytosed. As the folatelaced emulsion droplets were endocytosed, it was anticipated that the newly formed endosomes
would contain calcein at a self-quenching concentration. The calcein would not create a strong
fluorescent signal unless it was released from the endosomes and diluted into the cytosol. After
2 hours, the cells were thoroughly washed and some samples were exposed to 20-kHz ultrasound
for 2 seconds at 1 W/cm2. The cells were then scraped from the well surface and viewed by
confocal microscopy. Control experiments were performed by repeating the procedure in the
absence of emulsion droplets; a solution of calcein and DSPE-PEG2000-folate at similar
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endosomes were disrupted and the encapsulated calcein was released into the cytosol and
allowed to diffuse through most of the cell.

Figure 41. Folated PFC6 emulsions and concentrated calcein were endocytosed into HeLa cells. 20 kHz
ultrasound was applied to some of the cells for 2 seconds at 1 W/cm2. When cells were not exposed to
ultrasound (A and B) the quenched calcein was not released into the cytosol. Calcein could be observed
through the cells when exposed to ultrasound (C and D). Panels A and C are fluorescent confocal images and
panels B and D are light images.

Figure 41 shows the results when cells were exposed to PFC6 emulsions. Similarly, there
was a large increase in green fluorescence after exposure to ultrasound. However, the average
fluorescence intensity per cell was significantly less than in cells that had been exposed to PFC5
as determined with ImageJ software. This suggests that the vaporization of PFC6 emulsions was
less efficient for endosomal escape. This is most likely because of the lower vapor pressure of
PFC6; fewer droplets may have vaporized, or the expansion and resulting cavitation events may
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have been less violent. The difference in calcein release and subsequent fluorescence intensity
seems analogous to release from eLiposomes; both PFC5 and PFC6 were able to generated
release, but PFC5 was more complete or efficient.

Figure 42. HeLa cells were incubated with calcein and DSPE-PEG2000-folate but without emulsion droplets.
Cells in panels A and B were not exposed to ultrasound. Cells in panels C and D were exposed to 20 kHz
ultrasound for 2 seconds at 1 W/cm2. Without emulsion droplets present, there was not a significant
difference in endosomal escape of the calcein when ultrasound was applied. Panels A and C are fluorescent
confocal images and panels B and D are light images.

Figure 42 shows the results of a control experiment. Cells were exposed to the same
concentrations of calcein and DSPE-PEG2000-folate as in active experiments, but without the
presence of emulsion droplets. The cells in Figure 42C and 42D were exposed to 20-kHz
ultrasound for 2 seconds at 1 W/cm2. A slight green color can be seen in some cells. The
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amount of green fluorescence is comparable to samples that had included emulsion droplets but
not been exposed to ultrasound and is less than the amount of calcein observed throughout the
cells when emulsion droplets are present and the cells are exposed to ultrasound. Control
samples were viewed that had not been exposed to ultrasound and no green was detected at the
microscope parameters that were used, indicating that this green is indeed from calcein and not
from cell auto fluorescence. This baseline fluorescence could be due to some calcein passing
through the cell membrane or escaping from the endosome without bursting the membrane when
the cells are exposed to concentrated calcein. Confocal slices of some cells were viewed in order
to verify that the green fluorescence could not be attributed to calcein on the surface of the cells.
The resulting images verified that the observed calcein was on the interior of the cells.
Compared to controls, both PFC5 and PFC6 emulsions were able to induce endosomal
escape, evidenced by the dilution of self-quenched calcein throughout the cell. It is likely that
PFC5 emulsions form more persistent bubbles. The expansion of these persistent bubbles may
be more complete, more chaotic or more violent than PFC6, resulting in more release from the
endosomes. While PFC5 may have the advantage of more completely releasing contents from
the endosome, PFC6 may also be useful due to increased stability of the droplets and the
potential reversibility of the phase change.

It is encouraging that both PFC5 and PFC6

emulsions have the potential to aid in endosomal escape when exposed to ultrasound.

7.2 Intracellular calcein delivery with eLiposomes
7.2.1 Vesicle uptake at different diameters
In order to test the ability of cells to endocytose vesicles the sizes of our eLiposomes,
vesicles of DPPC and DSPE-PEG200-folate were prepared with 0.05 mM calcein at 800-nm and
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at 200-nm by film hydration and extrusion through membranes with 800 nm and 200 nm filter
pores.

At this concentration, the calcein is not self-quenched, and the liposomes create a

fluorescent signal when viewed via confocal microscopy. Cells were grown for the final 48
hours in folate free media. The calcein containing liposomes were added to the cells and allowed
to incubate for 2 hours prior to being viewed on the confocal microscope.

Figure 43. Cells were incubated with 200 nm (Panels A and B) or 800 nm (panels C and D) vesicles
containing 0.05 mM calcein for 2 hours. Vesicles of both sizes were internalized into the cells. Panels A and
C are fluorescent confocal images and panels B and D are light images.

Figure 43 demonstrates the uptake of vesicles of both sizes. Control samples (without
folate) run at this calcein concentration did not show any green at the microscope settings that
were used. The ability to detect green fluorescence with both 800-nm and 200-nm vesicles
shows the ability of the cells to internalize both samples. It should also be mentioned that the
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800-nm samples typically do contain some liposomes with smaller diameters, which may be
internalized more readily than the vesicles with a true 800-nm diameter. While both sizes show
the ability to endocytose in vitro, it is worth remembering that each size has advantages and
disadvantages: the 200-nm vesicles release less of their drug load when exposed to ultrasound,
but could penetrate deep into tissues via the EPR effect. In contrast, the 800-nm vesicles may be
induced to release more of their drug load, but may not have the ability to extravasate into
tissues.

7.2.2 In vitro ultrasound-induced delivery of calcein from eLiposomes to HeLa cells
In order to test the ability of eLiposomes to deliver a drug load to the cytosol of cells, 200
nm eLiposome samples were prepared with concentrated (15mM) calcein inside.

This

concentrated calcein does not fluoresce significantly while encapsulated inside of the vesicles.
Fluorescence increases as the calcein is diluted into the larger volume of the cell. Conventional
liposomes with encapsulated calcein at 15 mM were also prepared as a negative control. Some
of the external calcein was removed by settling. Additional calcein and the external emulsion
droplets were removed by the “sucrose cushion” technique. 200 µL of the various solutions
were added to each well of cells and allowed to incubate for 2 hours to allow the cells to
endocytose the vesicles. After the 2 hours of incubation, some cells were exposed to 20-kHz
ultrasound at 1 W/cm2 (MI = 1.22) for 2 seconds.
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Figure 44. HeLa cells that have been incubated with 200-nm eLiposomes or control vesicles containing
concentrated (self-quenched) calcein. After incubation to allow internalization of the vesicles, some samples
were exposed to 2 seconds of 20-kHz ultrasound at 1 W/cm2. eLiposome samples demonstrated much more
calcein throughout the cells when exposed to ultrasound. Samples with control liposomes did not
demonstrate significant amounts of calcein delivered to the cells with or without ultrasound exposure.

Figure 44 demonstrates the resulting calcein release to cells.

PFC6 eLiposomes

demonstrated the ability to sequester the majority of their calcein prior to insonation, followed by
the release of calcein to the interior of the cells when exposed to ultrasound (Figure 44A). When
ultrasound was not applied to the cells, the concentrated calcein was not released into the
cytosol.

The self-quenched calcein that remained inside of the eLiposomes did not add

significantly to the fluorescence of the cells. Similarly, PFC5 eLiposomes demonstrated the
ability to deliver calcein to the interior of the cells when exposed to ultrasound and the ability to
sequester the calcein when not exposed to ultrasound (Figure 44 B). PFC5 eLiposomes were
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able to deliver significantly more calcein to the cytosol than PFC6 as evidenced by increased
green fluorescence intensity in the cells as measured by ImageJ. This could be due to an
increased ability to vaporize and release from the eLiposomes (see Chapter 6) or from an
increased ability to break out of the endosomes due to irreversible and/or more chaotic
vaporization and gas cavitation. Control vesicles showed little to no ability to deliver the calcein
to the interior of the cells with or without exposure to ultrasound (see Figure 44C).

7.2.3 Evidence of folate-induced endocytosis, and endosomal release
In order to verify the importance of folate on the surface of the eLiposomes to stimulate
endocytosis, samples were prepared with encapsulated calcein at a self-quenching concentration.
DSPE-PEG2000-folate was added to the surface of some of the samples. The eLiposome
samples were incubated with HeLa cells for 2 hours, followed by exposing the cells to 20-kHz
ultrasound at 1 W/cm2 for 2 seconds. When the eLiposomes did not include folate, only a small
amount of green fluorescence could be observed in the cells (see Figure 45A). In contrast,
samples that contained folate on the surface of the eLiposomes demonstrated significant calcein
release to the cells (Figure 45C). When cells were incubated with calcein without eLiposomes or
emulsions and exposed to ultrasound there was not a significant amount of green fluorescence
detected (see Figure 42). These results suggest that the eLiposomes are not internalized into
cells without folate. When folate is included in the eLiposomes, they not only are internalized
but can be induced to release their contents with ultrasound.
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Figure 45. eLiposomes containing self-quenched calcein were prepared without folate (Panels A and B) or
with folate (panels C and D). The eLiposomes were added to HeLa cells and allowed to incubate for 2 hours.
The cells were then exposed to 2 seconds of 20-kHz ultrasound at 1 W/cm2. Cells that had been incubated
with folated eLiposomes had calcein throughout the cells. Panels A and C are fluorescent confocal images
and panels B and D are light images.

In order to further investigate the location of eLiposomes in cells before and after
sonication, eLiposome samples were prepared with a non-quenching calcein concentration (0.05
mM). LysoTracker was added to cells and allowed to incubate for at least 30 minutes in order to
allow the dye to penetrate the cells. Various concentrations of LysoTracker red dye were tested
to try to improve contrast and locate the endosomes. The best concentration was determined to
be 50 nM; higher and lower concentrations did reveal the location of the endosomes, but at lower
concentrations the contrast was poor, and at higher concentrations the red fluorescence tended to
dominate the majority of the cell.

The two fluorescent molecules were imaged in series;

LysoTracker dye was imaged using the helium-neon laser and the calcein was imaged using the
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argon laser. Figure 46 provides an example of cells with both dyes. When ultrasound was not
applied, the calcein tended to be localized in bright bunches and spots that were co-localized
with the LysoTracker Red, suggesting that the eLiposomes were located in endosomes and/or
other acidic vesicles (see Figure 46A). After ultrasound exposure, the green calcein was spread
throughout the cells. The location of the calcein and the LysoTracker Red dyes (green and red,
respectively), was no longer co-localized.

These results suggest that prior to ultrasound

exposure, the eLiposomes were inside of the endosomes. After ultrasound, the calcein had not
only been released from the eLiposomes, but had also escaped from the endosome (see Figure
46B).

Figure 46. HeLa cells were incubated with PFC5 eLiposomes and with LysoTracker Red dye. Cells were
imaged by confocal microscopy before (A) and after (B) ultrasound exposure. Calcein was co-localized with
the LysoTracker in Cells that had not been exposed to ultrasound, indicating that eLiposomes were located in
endosomes. After ultrasound exposure, the calcein had been released into the cytosol and spread throughout
the cell.

135

8

CONCLUSIONS AND RECOMMENDATIONS

8.1 Summary and conclusions
The motivation behind this work was to explore the ability of ultrasound to vaporize
emulsion droplets with high vapor pressures. This ultrasound-induced phase change may have
applications in drug delivery; the emulsion droplets themselves may act as drug carriers or their
vaporization may be able to trigger drug release from other drug carriers.
Emulsion droplets were successfully formed with PFC5 and PFC6.

These

perfluorocarbon liquids were chosen due to their biocompatibility, low solubility in water, and
high vapor pressures. Due to its biocompatibility and its ability to stabilize the emulsion droplets
at low concentrations, DPPC was chosen as a stabilizing surfactant. Sonication and mechanical
shaking were explored as potential methods for emulsion formation, and sonication was chosen
for the majority of this work due to its robust ability to form emulsions with relative ease of
application. Because the liquids used for the emulsions have high vapor pressures, the emulsions
were formed at low temperature on an ice bath. Attempts to form emulsions at room temperature
resulted in premature vaporization and foam formation. After sonication, the droplets usually
had a diameter between 200 and 400 nm and resulting emulsions were typically bimodal. The
size of the emulsion droplets was effectively reduced and controlled by extrusion through
polycarbonate filters with a 50 nm or 100 nm pore size. The resulting emulsions had average
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diameters near the filter pore size. Extrusion also reduced multimodality. TEM was used to
visualize the droplets and verified the average sizes.
Vaporization of the emulsion droplets when exposed to ultrasound was verified with
microscopy and by examining the Fourier transform of the acoustic emissions produced by the
emulsion samples. Both of these techniques verified that emulsion droplets are vaporized when
exposed to ultrasound. The size of the emulsion droplets was determined to have an effect on
droplet vaporization. Specifically, large emulsion droplets generated acoustic phenomena that
are indicative of bubble cavitation at lower thresholds than small emulsion droplets. Large
droplets also generated larger bubbles than small droplets when viewed under a microscope.
This effect of droplet size is believed to be due to the Laplace pressure imposed on the droplet;
the interior droplet pressure increases as the radius decreases, therefore increasing the ultrasound
amplitude required for vaporization.

In order to vaporize a liquid emulsion droplet with

ultrasound, the applied negative pressure must overcome the liquid vapor pressure and the
Laplace pressure imposed on the droplet. When these conditions are not met, the liquid droplet
will remain in the liquid phase. At higher temperatures, the vapor pressure of the liquid is
increased, and thresholds for vaporization are reduced.
Emulsion droplets were encapsulated inside of liposomes by forming interdigitated lipid
sheets and subsequently refolding the sheets into closed vesicles in the presence of emulsion.
The resulting eLiposomes initially had a very broad and random size distribution. The upper
limit of this size distribution was controlled and reduced by extrusion. CryoTEM and negative
staining TEM demonstrated the closed structure of the eLiposomes and the encapsulation of
emulsion droplets.
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When exposed to ultrasound, eLiposomes released more calcein than negative controls,
including liposomes without any emulsions and liposomes with external emulsions. This is
consistent with the hypothesis that internal emulsion droplets vaporize and expand when exposed
to ultrasound. When the droplets are encapsulated inside of a liposome, the expanding gas phase
seems to be able to disrupt the bilayer membrane. External emulsion droplets, however, did not
have an effect on the vesicles at short ultrasound exposure times. As exposure time increased,
external droplets had a slight effect, but only result in a slight increase in calcein release
compared to control experiments without emulsion droplets.

As expected, the size of the

emulsion droplets had a significant effect on their ability to induce calcein release from
eLiposomes; eLiposomes containing small emulsion droplets required higher ultrasound
intensities in order to release a comparable amount of calcein than eLiposomes with large
droplets. The size of the vesicles had an effect on the ability of eLiposomes and conventional
liposomes to release their calcein, with larger vesicles releasing more of the encapsulated load.
Herein, many different combinations of eLiposome size, emulsion droplet size, and
ultrasound parameters were explored. There are a number of aspects to be considered in order to
design the “ideal” eLiposome. Namely, larger droplets and vesicles tend to release more of their
encapsulated load, but smaller structures would be more useful for passive drug targeting. Also,
the eLiposome should retain the ability to sequester a large drug load along with emulsion
droplets. In general, it is likely that that an eLiposome with a 200 to 300-nm outer membrane
containing 100-nm PFC5 droplets would best balance these competing parameters. For
treatments where passive drug targeting is not desired, 800-nm vesicles with large droplets
would be most efficient. Obviously there are a large number of experiments that need to be
conducted in order to quantitate and optimize these design parameters.
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After decreasing the pressure sufficiently, a vapor phase should nucleate and expand
during phases of low pressure and rupture the eLiposome membrane. The required ultrasound
intensity for vaporization and time for nucleation should result in some kind of intensity
threshold for calcein release from eLiposomes. However, obvious thresholds were not observed
with respect to time or intensity despite operating at ultrasound parameters above and below
those calculated to overcome both the Laplace pressure on the droplets and the difference
between the local pressure and the droplet vapor pressure. This lack of obvious thresholds is
most likely due to the distribution of sizes in both emulsion droplets and eLiposomes. The
distribution of emulsion sizes imposed different Laplace pressures from droplet to droplet. Some
emulsion droplets will therefore require higher or lower negative pressure in order to vaporize
and this distribution may be responsible for the lack of a sharp intensity threshold for calcein
release. Furthermore, nucleation probably does not occur instantly, but may be a random process
that is related to the degree of sub-pressurization of the emulsion. The experimental data
indicate that nucleation occurs, but there may be a distribution in nucleation times that may
smear out a theoretically sharp threshold in experimental data.
The effect of delayed gas nucleation is further evidenced by the effects of time. If droplet
vaporization were instantaneous, a single ultrasound cycle with sufficient amplitude would
rupture the eLiposomal membrane and release the encapsulated contents. However, calcein
release from eLiposomes continued to increase with increasing exposure times up to at least 30
seconds.

Furthermore, ultrasound frequency also had an effect on calcein release from

eLiposomes.

Theory would suggest that the amount of negative pressure imposed by the

ultrasound wave should predict its ability to vaporize the emulsion droplet.

However, as

ultrasound frequency increased, much higher intensities were required to produce calcein release.
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This increase in release at lower frequency is most likely tied to the longer duration of the
rarefactional phase of ultrasound, thus providing more time for gas nucleation and expansion.
Temperature was expected to have a significant effect on calcein release from
eLiposomes due to the increased vapor pressure of the perfluorocarbon liquids at increased
temperature. While there was an increase in calcein release at higher temperatures, this increase
was less substantial than expected based on the change in vapor pressure with temperature.
Folated emulsion droplets demonstrated the ability to be internalized into HeLa cells via
endocytosis.

Calcein was released from the resulting the endosome when ultrasound was

applied. Likewise, both 200-nm and 800-nm eLiposomes were endocytosed into cells when the
vesicles were folated. Upon ultrasound exposure, the calcein that had been encapsulated within
the eLiposomes was not only released from the eLiposomes, but was also released into the
cytosol.

8.2 Recommendations for future work
The work described in this dissertation explores the potential of acoustic droplet
vaporization to be used in drug delivery applications. The details included herein add to the
existing understanding of this process. Specifically, the ability of perfluorocarbon emulsions to
vaporize and form persistent or non-persistent cavitating bubbles has been described.

A

hypothesis presented herein but not fully explored is that gas nucleation is a stochastic process
and a limiting factor in this phase change. While the ultrasound parameters employed in this
study were relatively mild, rapid drug release was not observed at predicted thresholds. An
attempt to further understand gas phase nucleation in emulsion droplets would represent a
significant advance in the understanding of acoustic droplet vaporization. It is possible that
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additional nucleating agents could further lower time and intensity thresholds for emulsion
vaporization.
For the purpose of drug delivery, it would be advantageous to speed up and enhance gasphase nucleation so that emulsions may be used for drug delivery at ultrasound parameters with
low energy exposures. If the nucleation process can be sped up, droplets could be induced to
vaporize rapidly at high frequency in order to create a safe targeted system that behaves in an
on/off fashion. Alternatively, it is possible that other targeting modalities such as heat or IR light
could induce droplet vaporization in more of an on/off fashion compared to ultrasound.
Another area of potential exploration is a better understanding of the effect of frequency
on droplet vaporization.

This dissertation reports that higher frequencies required higher

intensities in order to induce vaporization. However, only 2 frequencies were tested at only a
handful of intensities. A study that explores several frequencies and a variety of ultrasound
parameters, including intensity, pulse length, and pulse frequency, would not only add a more
complete understanding of ultrasound-induced vaporization, but could also identify more useful
ultrasound parameters.
While eLiposomes demonstrated an enhanced ability to release encapsulated contents
when exposed to ultrasound, other techniques have also made similar advances.

Namely,

ultrasound sensitive liposomes have been developed using non-traditional lipids to form the
bilayer, and “echogenic liposomes” have been developed with the claim that small amounts of
gas or air are encapsulated in the liposome. While each of these systems will have its own set of
advantages and disadvantages, an objective comparison may prove useful. Particularly, the
following questions should be answered: how does the ultrasound-induced delivery of
encapsulated contents compare at similar ultrasound intensities?
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Can the various types of

liposomes be formed with diameters between 100-300 nm in order to take advantage of the EPR
effect? Do the lipids and other materials of construction allow the liposomes to efficiently
sequester a drug load prior to ultrasound activation? How does this sequestering efficiency
compare to conventional liposomes?
Purification of eLiposomes, including removal of external emulsion droplets and the
removal of unencapsulated calcein (or drug), remains a challenge. The separation methods used
herein include the sucrose cushion technique and vesicle settling. These techniques and/or other
separation methods should be further developed and perfected.
The 2-step sheet refolding method for droplet encapsulation that is presented in this
dissertation provided an interesting way to form eLiposomes, but also presents significant
challenges. Using this 2-step process to form eLiposomes is complicated and cumbersome and
is probably not practical on an industrial scale. Furthermore, there are formulation constraints
that affect the ability to form and refold sheets. Most notably, cholesterol cannot be added to the
sheets at concentrations that are typically used in liposomal formulations. As mentioned in
Chapter 2, cholesterol is typically used in commercial liposomes and is cited as preventing the
liposomes from being quickly broken down in the blood stream. Efforts have already begun to
explore other techniques for forming eLiposomes that will allow more versatility with lipid
formulations and also will allow the addition of cholesterol. These methods should be further
explored and perfected. The finalized eLiposomes should include cholesterol and PEGylated
lipids. The ultrasound sensitivity of the new eLiposome formulation should be characterized
similar to the work performed in this dissertation.
After eLiposomes have been further developed, in vivo targeting will be an area of
particular interest. This dissertation describes the intracellular delivery of calcein, enhanced by
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folated drug carriers. The ability to selectively target cancerous tissues in vivo via active
targeting ligands and by the EPR effect will be an important process to verify and to
characterize. The effectiveness of eLiposomes to reduce tumor size should also be characterized.
Prior to these studies, eLiposomes will need to be loaded with active anti-cancer drugs.
This dissertation has detailed initial in vitro studies that suggest that the vaporizing
emulsion droplets can aid in drug delivery without killing the target cells. As is the case with all
ultrasound-mediated drug delivery, there may be thresholds where the expanding vapor may
damage and/or kill cells. A more quantitative study of cell viability when exposed to emulsion
droplets and ultrasound may prove useful, especially when the emulsion droplets are taken into
the cells and may have the potential to disrupt the cell membrane. Internal emulsion droplets
have shown the potential to disrupt endosomal membranes, and there may be a fine balance in
order to take advantage of that potential without damaging cells. Gene delivery is another
potential use for vaporizing emulsion droplets, particularly because of the potential endosomal
escape of the delivered nucleic acids. Emulsion droplets may be useful in this type of treatment
individually or as part of eLiposomes. In order to explore this potential, an effective method for
loading nucleic acids into eLiposomes should be developed. The potential to deliver a variety of
nucleic acids could then be explored both in vitro and in vivo.
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